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ABSTRACT
Pharmaceutical firms typically enjoy market exclusivity for new drugs from concurrent protection of
the underlying invention (through patents) and the clinical trials data submitted for market approval
(through data exclusivity). Patent invalidation during drug development renders data exclusivity the
sole source of protection and shifts the period of market exclusivity at the project level. In instrumental
variables regressions we quantify the effect of a one-year reduction in expected market exclusivity on the
likelihood of drug commercialization. The effect is largely driven by patent invalidations early in the
drug development process and by the responses of large originators. We hereby provide first estimates
of the responsiveness of R&D investments to market exclusivity expectations.
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1 Introduction
The negotiations of the Trans-Pacific Partnership (TPP) – a trade agreement among initially twelve
Pacific Rim states accounting for about 40% of the global economy – took more than five years and
were closely followed by the public. TPP put the discussion on the design of intellectual property
rights that protect new drugs against imitation and generic competition back on center stage (Luo
and Kesselheim, 2015). In particular, the period of data exclusivity for novel pharmaceutical prod-
ucts and biological medicines was one of the most controversial issues. Data exclusivity refers to
the period during which clinical trial results, detailing the approved drug’s toxicology and efficacy,
cannot be used by generic entrants for subsequent marketing approval. As clinical trials are costly,
data exclusivity creates entry barriers and hence is a source of market exclusivity independent of
patent protection. In a broader context, the debates around an extension of data exclusivity periods
evolved around the trade-off between welfare gains arising from stronger incentives to innovate and
additional cost to society due to (near) monopoly pricing. On the one hand, strengthening the legal
protection of novel drugs might increase the incentives to invest in risky R&D projects and yield
more desirable new drugs. On the other hand, extending exclusivity rights might lead to welfare
losses created by higher prices due to limited competition by generics. In fact, countries with either
no or short data exclusivity periods1 opposed demands for a uniform extension of data exclusivity to
up to twelve years, referring to the risk of rising health care costs and restricted access to pharma-
ceuticals. The United States of America, in contrast, emphasized the role of longer data exclusivity
periods in the provision of incentives to invest in the development of new drugs.2
The trade-off between stronger incentives for innovation (stronger protection against imitation)
and resulting costs to society (higher prices) has been well established in the innovation literature
(Arrow, 1962). Starting with Nordhaus (1969), a broad stream of theoretical literature provides
analyses of the optimal design of intellectual property rights and the balance between dynamic
social gains by greater innovation efforts and static losses due to granting monopoly power to inno-
vators (see Scotchmer (2004) for a comprehensive discussion). The more recent empirical literature
increasingly focuses on the causal relationship between intellectual property rights and inventive ac-
tivity, analyzing both the rate and the direction of innovation in the pharmaceutical industry (Bud-
ish et al., 2015; Kyle and McGahan, 2012; Qian, 2007) and beyond (see Williams (2017) for an
overview). Most of the existing theoretical and empirical work on innovation in the pharmaceutical
industry, however, focuses on incentives provided by the patent system without taking into account
its complex interplay with data exclusivity.3 In this paper, we contribute to this literature by relating
the overall duration of market exclusivity resulting from both patent protection and data exclusivity
1There exists no data exclusivity in Brunei. Australia, Chile, Malaysia, Mexico, New Zealand, Peru, Sin-
gapore, and Vietnam all provide relatively short periods of data exclusivity to originators.
2The talks on the Trans-Pacific Partnership were successfully concluded on October 4, 2015, and officials
from the twelve participating countries signed the agreement on February 4, 2016. Whereas the United States
of America’s withdrew from the trade agreement in January 2017, the remaining eleven countries signed the
deal on March 8, 2018 – with all provisions related to data exclusivity suspended.
3Budish et al. (2015) is a notable exception as they discuss the effect of data exclusivity in the theoretical
section of their paper.
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to the likelihood of successful product commercialization in the pharmaceutical industry. Ultimately,
we hereby provide estimates for the responsiveness of R&D investments to a change in the duration
of market exclusivity.
The overall duration of market exclusivity for a new drug is derived from patents as well as data
exclusivity and determined by the time between initial patent filing and market approval: patents
grant exclusive rights to inventions (in our context: molecules) for a fixed period of time start-
ing from the date of the patent application. In most cases, patent applications are filed upon the
discovery of the molecule underlying a potential drug and mark the beginning of a lengthy devel-
opment project in which pre-clincal and clinical tests have to be conducted. Data exclusivity, in
contrast, is granted for a fixed period upon the approval of a new drug for marketing. At market
approval, a new drug enjoys concurrent protection from the remaining patent term and from the
fixed period of data exclusivity. If the remaining patent term at market approval is shorter than the
period of data exclusivity, the latter provides additional protection. During the TPP negotiations it
was argued that, in the light of increasing durations of clinical trials and the implied reduction of
effective patent terms, extended data exclusivity periods could remedy weakened R&D incentives.
In their theoretical analysis of potential policy responses to skewed R&D incentives resulting from
fixed patent terms, Budish et al. (2015) come to the same conclusion.
Despite the intense policy debate surrounding the optimal design of intellectual property rights
in the pharmaceutical industry, there is little empirical evidence on how the overall duration of mar-
ket exclusivity relates to originators’ innovation efforts. An ideal experiment to study this question
would randomly allocate varying durations of market exclusivity to firms ex ante and link them to
observed innovation outcomes. Such an experiment is infeasible. As an alternative, we exploit a
natural experiment that provides exogenous variation in the patent protection surrounding a drug
development project. In particular, we analyze development histories of drugs for which underlying
patents have been at risk of invalidation in opposition proceedings at the European Patent Office
(EPO): when a patent is invalidated, data exclusivity becomes the sole source of market exclusiv-
ity. If the remaining patent term after drug approval exceeds the period of data exclusivity, patent
invalidation will lead to a reduction in the overall duration of market exclusivity. We compare the
outcomes of these treated development projects with outcomes of projects where patents have been
upheld in opposition (and market exclusivity remains unaffected). Linking the project-specific ex-
ogenous variation in the duration of market exclusivity to drug development projects’ outcomes
enables us to causally identify how the duration of market exclusivity determines innovation efforts.
We account for the fact that our treatment (invalidation) might not be random as firm efforts put
into defending a patent are likely to be determined by unobservable characteristics (such as early
signs of a drug’s efficacy or potential market size) that may also affect innovation efforts. To ad-
dress the resulting endogeneity of patent invalidation in our empirical analysis, we employ a novel
instrument first proposed by Gaessler et al. (2017). This instrument uses random variation in the
participation of the primary examiner, who initially granted the patent, in the opposition proceeding.
Examiner participation is negatively correlated with patent invalidation but uncorrelated with other
factors that might determine originators’ commercialization efforts. Instrumenting patent invalida-
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tion hence creates exogenous variation that allows us to causally identify how innovation outcomes
depend on the duration of protection against generic competition.
For our study, we construct a novel data set that links the development histories of pharmaceu-
tical compounds from pre-clinical trials up to market approval (or the highest development stage
reached) with information on the underlying patents. Clarivate’s Cortellis database and the EPO’s
PATSTAT statistical database are the major sources of our data. In total, we are able to link 920
unique drug candidates and their respective development histories with patents subject to invali-
dation proceedings. Drug candidates are often tested against more than one specific indication, so
that one drug may be linked to multiple development projects. Ultimately, we identify 2,788 unique
observations at drug-indication level where the decision on opposition takes place before drug ap-
proval or the termination of clinical trials – a prerequisite for our empirical strategy. This sample
includes drug candidates from the full spectrum of therapeutic areas, yet still differs from the overall
population of (observable) drug projects. We focus on drug candidates that have entered at least
pre-clinical trials and where the validity of at least one underlying patent has been challenged. As a
consequence of this, these drug candidates are more valuable and promising compared to the overall
population. This renders our estimates conservative as firm decisions should be less responsive to
changes in the duration of market exclusivity for drug candidates with a high expected value.
We present estimates from linear probability models in which we relate commercialization out-
comes to the overall duration of market exclusivity for development projects with and without patent
invalidation. Our IV regression results indicate that a reduction in the overall duration of market
exclusivity significantly affects project outcomes. In fact, we find that the loss of one year of mar-
ket exclusivity lowers the likelihood of drug approval by about 3.5% relative to an unconditional
approval rate of 30.5%. This response to a loss in expected market exclusivity is quite immediate:
firms overwhelmingly abandon treated drug projects right after the patent is invalidated and do not
pursue the next development phase. We further find that the effect is driven by (i) timing, as patent
invalidation in early development phases has a statistically more significant effect and (ii) firm size,
as originators with large pipelines react more strongly to reductions of market exclusivity periods
than originators with small ones. We argue that the more elastic responses in these two subsamples
approximate the policy-relevant effect at the extensive margin, because in this context firms face
lower sunk costs (i.e., most of the R&D costs occur at later stages) but higher opportunity costs (i.e.,
alternative drug projects are readily available).
We conduct several robustness tests taking into account the complex institutional setting of this
study. First, as drugs are often protected by more than one patent, one potential concern is that
invalidation might not affect the primary patent associated to a drug’s active ingredient but rather
a secondary patent related to dosage or delivery channels. Considering primary patents exclusively,
we find results that are comparable to our main findings. Second, drug candidates are often tested
against multiple indications and results from pre-clinical and phase I clinical trials can – under
certain circumstances – be used across diseases. Restricting our sample to development histories of
first indication drugs does not change our results. Finally, our main results consider drug approvals
in any of the three largest pharmaceutical markets (US, Europe, Japan), even though we consider
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shifts of market exclusivity in European markets only. For this reason, our estimates should be
interpreted as lower bounds of the effect of changes in exclusivity across all markets. Robustness
tests using a subsample of biologic drugs, for which the data exclusivity regimes in Europe and the
US are comparable, indeed yield larger effect sizes.
The findings from this study bear relevance not only for scholars interested in the economics
of innovation but also for policy makers responsible for the design of law governing IP protection.
A further strengthening of the protection of new drugs by extending data exclusivity periods has
been discussed contentiously but largely in the absence of empirical evidence (Diependaele et al.,
2017; Grabowski et al., 2015; Higgins and Graham, 2009; Lietzan, 2016). Our work identifies how
the duration of market exclusivity affects originators’ commercialization efforts and quantifies how
variations in the durations of exclusivity determine private incentives to complete drug development.
Our findings have important implications: data exclusivity emerges as an effective policy instrument
to provide market exclusivity in cases where the remaining patent term is short relative to the lengths
of needed clinical trials, or where patent protection is uncertain.
2 Market exclusivity in the pharmaceutical industry
2.1 Institutional background
Context
The commercial life cycle of a drug consists of three periods (Scherer, 2000): (i) the development
period, during which R&D takes place and clinical trials are conducted; (ii) the market exclusivity
period, when the originator company markets the drug under exclusivity as imitation is prevented
by patents and/or data exclusivity; and (iii) the post-exclusivity period, in which competition by
generic products copying the initial drug is possible. The development period is highly regulated
and typically consists of the discovery stage, pre-clinical trials, and phase I, II, and III clinical trials,
which ascertain the toxicity and efficacy of a molecule. On average, it takes between 8.6 and 11.5
years from discovery to marketing authorization, and only a small fraction of all drug candidates
(molecules) entering development eventually reach regulatory approval (European Commission,
2009). In order to obtain marketing authorization in a given jurisdiction, originator companies
have to submit data gathered during clinical trials to respective national regulatory authorities and
request marketing authorization for specific markets.4 Developing new drugs is a costly endeavor
as evidenced by cost estimates in the range of USD 500 million to USD 2.6 billion (Adams and Van
Brantner, 2006; DiMasi et al., 2016). Tests and clinical trials are responsible for the majority of the
4While generally following the system of stage I, II and III trials, national regulatory bodies migh have
different requirements regarding the exact specification of clinical tests required for approval. In consequence,
clinical trials are sometimes conducted in different jurisdictions. Since 1990, the International Council for
Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), consisting of regulatory
bodies from the US, Europe and Japan and other countries, has provided a forum to increase international
harmonization of test requirements.
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Figure 1: Life cycle of pharmaceutical products
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Notes: This figure is a schematic presentation of the typical drug life cycle. SPC protection is optional and generic entry may occur
earlier due to authorized entry. Data exclusivity corresponds to the EU regulations of 2005 onward.
total R&D costs – the European Commission (2009) estimates that research-active pharmaceutical
companies spend only 1.5% of their overall revenues on basic R&D (which includes the discovery
of novel compounds) but 15.5% on clinical trials, tests, and market approval.
Pharmaceutical companies’ decisions to make risky high upfront investments in developing new
drugs largely depend on their expected pay-offs during the subsequent period of market exclusiv-
ity. Only if companies can expect to recoup R&D investments during the exclusivity period through
high mark-ups on prices before generic entry takes place, will initial investments in development be
made. Market exclusivity is derived through two legal mechanisms: patent rights and data exclusiv-
ity. Figure 1 presents a stylized life cycle of a drug and the associated intellectual property rights in a
schematic way. Upon discovery, companies typically file applications for patents covering the active
substance of a drug and subsequently obtain a grant decision. Once clinical trials are completed
and the collected data shows the non-toxicity and the effectiveness of a drug, it can be approved
for marketing by regulatory authorities. This marks the starting point of a drug’s period of market
exclusivity, whose length is determined by the effective patent term5 and the period of data exclu-
sivity. Longer periods of market exclusivity are related to higher pay-offs for the originator company.
After expiration of market exclusivity, generic manufacturers are likely to enter the market, which
reduces prices and consequently the originator company’s margins.
Pharmaceutical companies often seek to increase their R&D productivity either by broadening
the market for a molecule through additional medical indications or by extending the period of mar-
ket exclusivity through improved versions of the original drug. First, they might try to “reposition”
existing drugs for new indications (Ashburn and Thor, 2004). Repositioning is characterized by a
lower risk profile as these drugs have already been tested in previous clinical trials for at least one
alternative indication and therefore have known toxicological and efficacy profiles. Additionally, ex-
isting clinical data often allows pharmaceutical companies to bypass early steps in the development
5Several jurisdictions grant patent term extensions for pharmaceutical inventions. In Europe, patent
protection may be extended by filing a Supplementary Protection Certificate (SPCs); see below for details.
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funnel such as pre-clinical trials (Ashburn and Thor, 2004). The investments to reposition an exist-
ing drug are therefore significantly lower than those needed to develop a new drug. Second, R&D
productivity can be increased by extending the period of market exclusivity with the introduction
of follow-on products. These second-generation products typically are incremental improvements
of existing authorized drugs. The strategy of releasing second-generation products is called “ever-
greening” (Hemphill and Sampat, 2012). Originator companies often launch follow-on products
shortly before they lose exclusivity for the first-generation product. In order to guarantee market
exclusivity for the second-generation products, they typically continue to work on incremental im-
provements and obtain additional patents on these improvements throughout the life cycle of the
first product. These additional patents expire later than the primary patents on the original product,
extending the period of market exclusivity.6
Patent rights
Patents rights are exclusive rights that allow the patent holder to exclude third parties from using the
protected invention for a fixed term of 20 years starting from the original filing date (priority date
of the patent). Patents on a drug’s active ingredients are easy to enforce and allow patent holders
to prevent imitation and the entry of generic competition; they are considered the primary mech-
anism to appropriate value from innovation in the pharmaceutical industry (Cohen et al., 2000).
The patents covering a potential drug are typically filed at “drug discovery”, i.e., during the basic
R&D stage. For this reason, the duration of the resulting market exclusivity of the novel drug is
directly determined by how much time lapses between the filing of the patents and the drug’s mar-
ket approval (see the detailed discussion below). While originators generally target global markets,
patents are national rights. For this reason, patents on novel pharmaceutical substances are typically
filed internationally at several patent offices simultaneously.7 Patentability rules are largely harmo-
nized among the members of the World Trade Organization and international variation regarding
their duration and protective scope is negligible in the context of our study.
A number of jurisdictions provide mechanisms to extend the duration of patent protection for
pharmaceutical products under certain conditions. In Europe, if the period of market exclusivity
derived from patents is shorter than 15 years, companies can apply for so-called supplementary pro-
tection certificates (SPCs) for medicinal products according to Council Regulation (EEC) No 1768/92
of 18 June 1992 (see European Commission (2018) for details on the regulation of SPCs). SPCs ef-
fectively amount to an extension of the patent right for a maximum of five years as the total term of
market exclusivity derived from the patent plus SPC is limited to 15 years.8 In the United States of
America, the 1984 Drug Price Competition and Patent Term Restoration Act (“Hatch-Waxman Act”)
6For a detailed discussion of evergreening strategies, see European Commission (2009).
7The set of international patent applications covering a given substance is called a patent family.
8Even if marketing authorization is granted only 15 years after the priority date of a patent the originator
company can apply for an SPC of the maximum duration of five years, yielding a total period of exclusivity of
ten years. Further note that SPCs extend only to the specific medicinal product and use which was originally
authorized – they do not cover subsequent authorizations of the same compound for different indications.
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allows qualifying companies to apply for a partial extension of patent life based on the time that
the drug spent in clinical trials. Specifically, the act awards an additional half-year of patent life
for every year spent in clinical trials, up to a maximum of 5 years not exceeding 14 years of patent
protection in total (Saha et al., 2006). Note that in the following discussion, we focus on European
regulation.
Patents relating to a pharmaceutical product are typically divided into primary patents, pro-
tecting the active ingredient, and secondary patents, protecting all other aspects of a drug such as
different dosage forms, components, production methods, etc. Secondary patents often result from
originators’ efforts to extend the time of market exclusivity and to maintain or even expand the
market that the product covers during market exclusivity. These objectives can be supported by
specific patenting strategies, in particular the creation of so-called patent fences, i.e., the filing of
a multitude of patents surrounding one product (see Abud et al. (2015) and European Commis-
sion (2009) for more detailed discussions). Typically, the filing date (priority date) of the primary
patent(s) surrounding a pharmaceutical product determines the duration of market exclusivity of a
first-generation drug that can be derived from patents (and SPCs).
Data exclusivity
A second source of market exclusivity is data exclusivity, which protects the data collected in clini-
cal trials and submitted to regulatory authorities in the process of obtaining market approval for a
new drug. Before 1984 in the United States, and before 1987 in the European Union, pharmaceu-
tical test data was protected as a trade secret. The introduction of new harmonized procedures for
abridged applications for market approval of equivalent or essentially similar pharmaceutical prod-
ucts (“generic applications”) with the 1984 Drug Price Competition and Patent Term Restoration
Act (“Hatch-Waxman Act”) in the U.S. and the 1987 87/21/EEC Directive in the European Union
further clarified the rules of clinical test data protection.9 Data exclusivity (or test data protection)
prevents marketing authorization bodies from processing so-called abridged applications for mar-
keting a generic drug before a certain number of years after the first marketing authorization for the
originator product have elapsed. Only after a drug’s protection via patents (and SPCs) has lapsed
and in absence of data exclusivity, can generic companies file abridged applications. Abridged appli-
cations have the advantage that they do not require the applicant to provide results of pre-clinical
tests or clinical trials but only to demonstrate that a product is similar to the original drug. If a drug
still enjoys data exclusivity, however, generic entrants need to submit data from complete clinical
trials. In light of the costs of conducting clinical trials, data exclusivity creates a significant barrier
to entry for generic companies (Grabowski, 2004; Branstetter et al., 2017).
The duration of data exclusivity has not been harmonized internationally and is a subject of
ongoing policy debates around the globe. In Europe, it varied considerably across countries ranging
from six to ten years before the Directives 2001/83/EC and 2004/27/EC of the European Com-
9A more complete discussion on the legal regulations and their development over time in different juris-
dictions can be found in Sanjuan (2006).
7
mission harmonized data exclusivity regulations in Europe with legal effect from November 2005
(European Commission, 2009).10 For marketing authorization applications made from November
2005 onward, the period of data exclusivity in Europe was harmonized as eight years from the date
of first authorization in Europe with an additional period of two years.11 After a total period of ten
years from the grant of the innovator company’s marketing authorization, generic companies can
also market their product.12
2.2 Market exclusivity and the incentives for drug development
As profits in the pharmaceutical industry can be realized only after regulatory approval of a new
drug and its subsequent market launch, firms’ investment decisions in pharmaceutical R&D projects
can be characterized as forward-looking decisions weighing development costs against future prof-
its conditional on market approval (Lakdawalla, 2018; Scherer, 2010). Starting a broad theoretical
literature, Nordhaus (1969) argues that investments in the discovery of innovation rise with profits
expected from it. Based on this argument, it is straightforward to show that the duration of market
exclusivity is directly linked to investments into R&D in the pharmaceutical industry. In Appendix
C, we present an simple model of how a firm’s incentive to invest in risky R&D projects depends on
expected future profits which in turn depend on the (expected) duration of market exclusivity. In
this model, investments in R&D need to be made before the innovator can earn profits conditional
on having been successful in innovating. Further, investments in R&D increase the likelihood of
successful innovations. For the pay-offs from being successful, assume that an originator company’s
profits during a new drug’s period of market exclusivity pim are greater than its profits after generic
entry pic since competition is absent (Cohen et al., 2000; Mansfield, 1986; Levin et al., 1987). Sec-
ond, pim is increasing in the duration of market exclusivity as generic entry is delayed further. Under
these assumptions, a company’s incentive to invest in risky R&D is strictly increasing in the duration
of the market exclusivity. Note, we abstract from additional determinants of future profits including
market size, level of market saturation, and competitive dynamics in the targeted therapeutic area
(Acemoglu and Linn, 2004; Dubois et al., 2015; Krieger, 2017; Rao, 2018).
The actual duration of market exclusivity of successful development projects is determined by
patent protection, development time and the length of the data exclusivity period and varies across
10The following countries granted six years of data exclusivity: AT, BG, CY, CZ, DK, EE, ES, EL, FI, HU, IE,
IS, LI, LT, LV, MT, NO, PL, PT, RO, SE, SK. The following countries granted ten years of data exclusivity: BE,
DE, FR, IT, LU, NL, SE, UK.
11This additional period of two years is officially termed “market exclusivity”. Market exclusivity refers
to the period of time during which a generic company may not market an equivalent generic version of the
originator’s pharmaceutical product (although their application for authorization may be processed during
this period, such that they are in a position to market their product on the expiry of this additional two-year
period). To avoid confusion, we stick to “data exclusivity” as an umbrella term.
12The originator’s product may qualify for one further year of exclusivity. This additional year can be
obtained in a number of circumstances, such as where the innovator company is granted a marketing autho-
rization for a significant new indication for the relevant medicinal product. For these reasons, the regulation
taking effect in 2005 is often labeled as “8+2+1” and provides market exclusivity of up to eleven years (see
European Commission, 2009, p. 127).
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Figure 2: Market exclusivity as a function of drug development time
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Notes: This figure illustrates the relationship between development time and market exclusivity. SPC protection is optional. “Loss of
exclusivity” refers to the loss of market exclusivity due to patent invalidation.
development projects (see also Section 2.1, Figure 1). First, the effective patent term, i.e., the dura-
tion of patent protection while a new drug is on the market, is linearly decreasing in development
time as patents are filed at the beginning of the development stage. If a drug is approved only af-
ter five years of development or later, a company can obtain an SPC which extends patent-based
market exclusivity for another five years (limited to a maximum total duration of market exclusivity
of 15 years). Second, if the remaining effective patent term at approval is lower than the period
of data exclusivity, the overall duration of market exclusivity is determined by the duration of data
exclusivity independently of the development time. In the majority of cases (and as in our example
in Figure 1), the data exclusivity period expires before the lapse of relevant patents and SPCs. The
data exclusivity period extends beyond the patent term only in cases of relatively long development
times (European Commission, 2009). Figure 2 summarizes these relations between development
time and the duration of market exclusivity: The dark blue (solid) line represent the total period of
market exclusivity as a function of development time.
2.3 Firm responses to changes in market exclusivity
To date, there is little empirical evidence to what extent firms’ innovation activities respond to
changes in the expected duration of market exclusivity. The universal existence of harmonized
IP systems renders empirical studies of the effect of different market exclusivity periods on the de-
velopment of new drugs challenging. As a result, only limited empirical evidence exists on how
firms’ R&D investment decisions relate to the duration of market exclusivity. Moreover, since R&D
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expenditures on the project level are hard to observe, scholars typically take observable product
development projects as indicators of innovation activity. Most relevant to our study, Budish et al.
(2015) argue that, in contrast to the fixed patent length, the effective duration of patent protection
varies. Innovations that can be commercialized at the time of invention enjoy patent-based market
exclusivity of the full patent term, whereas innovations that have a long time lag between invention
and commercialization (such as drugs) receive only a substantially reduced period of patent-based
market exclusivity. Budish et al. (2015) show that firms disproportionately invest in projects with
longer effective patent protection and discuss negative welfare effects due to this distortion. Wagner
and Wakeman (2016) provide additional evidence on the link between patent protection and drug
commercialization. Looking at variation in patent grant lag, they find that once the uncertainty
about patentability is resolved, the likelihood and speed of successful drug development increase
significantly.
Adding to this sparse literature, we study how firms’ innovation activities respond to variation
in project-specific market exclusivity durations and exploit a natural experiment that provides ex-
ogenous variation in the patent protection surrounding a drug development project. While patent
applications are thoroughly examined in a time-consuming process (Popp et al., 2004; Harhoff and
Wagner, 2009), granted patents are generally at risk of invalidation after they have been granted. In
case of invalidation, data exclusivity becomes the sole source of market exclusivity. If the remaining
patent term from the invalidated patent exceeds the period of data exclusivity, patent invalidation
will reduce the duration of market exclusivity; we refer to this reduction simply as loss of exclusivity
(see also Figure 2). We focus exclusively on development projects where the underlying patent has
been at risk of invalidation before project completion. Comparing outcomes of development projects
with and without an actual loss of exclusivity allows us to measure the responsiveness of firms’ R&D
activities to changes in the overall duration of market exclusivity.13
As an in-depth discussion of the institutional details surrounding patent invalidation is beyond
the scope of this paper, we restrict ourselves to briefly highlighting key aspects in Europe and their
counterparts in the United States. In Europe, the validity of a patent can be challenged by any
third party in court any time after its grant. In addition, the European Patent Office (EPO) offers the
possibility to challenge a patent’s validity within nine months after its grant. Opposition proceedings
at the EPO are governed by Section V of the European Patent Convention (EPC). Opponents can
challenge patents for grounds specified in Article 100 EPC, which relate to the subject-matter of
the patent not being patentable, failure to disclose the invention clearly and the patent’s subject-
matter extending beyond the content of the application. The opposition division, which consists
of three technically qualified EPO patent examiners, at least two of whom have not taken part in
the grant of the opposed patent), decides on the opposition. Possible outcomes are a narrowing of
the protective scope of a patent (amendment) or the patent’s entire invalidation (revocation). A
13Note that our research design allows us to identify the intensive margin only. In order to identify the
extensive margin, one would need to observe projects that are not put into trials by pharmaceutical firms
expecting a weak IP position and short periods of market exclusivity. We discuss how our results relate to the
extensive margin at a later point in the paper.
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structurally equivalent mechanism of post-grant validity challenges at the United States Patent and
Trademark Office (USPTO) (’Post Grant Review’) was introduced with the Leahy-Smith America
Invents Act (AIA), which went into effect on September 16, 2012. Since opposition proceedings are
significantly less costly than validity challenges in national courts, they represent the main channel
of patent invalidation in Europe (Harhoff and Reitzig, 2004). Between 1980 and 2007, about 7.4%
of all granted pharmaceutical patents at the EPO have been opposed at the patent office (Harhoff
et al., 2016).
Third parties typically challenge patents of higher value (Harhoff and Reitzig, 2004), but there is
little evidence about the underlyingmotives of the opponents. Unlike the US, there are no formalized
incentives for third parties to challenge the validity of patents protecting novel drugs in Europe.14
While invalidation of a patent via opposition has the potential to reduce the market exclusivity
period of a drug, opposition has be filed years ahead of a potential generic entry at a point in time
where it is not even clear whether a drug candidate will eventually be approved at all. Preliminary
evidence points to “legal spillovers”, where patent invalidation through opposition at the EPO calls
into question the validity of the patent’s counterparts in other jurisdictions.15 Gaessler et al. (2017)
finds similar spillover effects for follow-on innovation. Hence, opposition outcomes at the EPO can
be expected to be correlated with the strength of the IP protection of a drug candidate in other
jurisdictions.
Models of firm investments into the discovery and development of innovation predict that invest-
ments rise with the profits expected from it. As the profits from successful drug development increase
in the duration of market exclusivity, we expect a loss of exclusivity due to patent invalidation to have
a negative effect on firms’ innovative activities. As we are not able to measure project-specific R&D
investments directly, we relate a loss of exclusivity to observable project-specific likelihoods of suc-
cessful product commercialization and project continuations, which can be expected to be strongly
correlated to underlying investments. In our context, patent invalidation that reduces the expected
duration of market exclusivity is expected to lower the likelihood of project continuation and thus
commercialization. Given that we have considerable variation in the loss of exclusivity across our
sample, our research design allows us to provide a first quantification of firms’ responsiveness to
market exclusivity durations in the pharmaceutical industry.
There are at least two sources of heterogeneity that may affect the magnitude of our main effect.
First, we expect its strength to depend on the timing of patent invalidation relative to a drug can-
didate’s position in the development process. Having completed a given stage of the development
process, originators must decide whether to further invest in the next phase of trials or to abandon
a project. In this setting, a negative shock to the expected profits from successful commercializa-
14In the US, the “Hatch-Waxman Act” provides incentives for generics companies to challenge patents pro-
tecting new drugs. Generics companies that file an Abbreviated New Drug Application (ANDA) under Para-
graph IV before a patent has expired are granted a 180-day exclusivity period to market their generic version
of the drug without any further generic entry allowed (Branstetter et al., 2016). The European regulations
do not have an equivalent to these Paragraph IV challenges.
15With uniform requirements for patentability, the US counterpart of an EP patent is prone to the same
novelty-destroying prior art (independent of origin and language) (Merges, 2012).
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tion due to a loss of exclusivity will affect firm responses stronger if it materializes in early stages.
This prediction is in line with general models of staged investment decisions and optimal stopping
problems (Dixit and Pindyck, 1994; Pindyck, 1991): The probability of success (obtaining market
authorization) and hence the expected pay-off from investments in subsequent development stages
increases with each completed trial stage. At the same time, both uncertainty and the total cumu-
lative amount of further investments necessary to reach the market decrease. As prior investments
in a drug candidate are generally considered to be sunk, a reduction of the final pay-off at a later
stage of drug development should have a smaller effect on investment incentives when compared
to a loss of exclusivity that materializes early in the process.
Second, the magnitude of our main effect should also depend on firm size. Firms likely differ
in the availability of alternative investment projects (outside options) when assessing a given R&D
project (Chan et al., 2007; Girotra et al., 2007; Kavadias and Loch, 2004). Most relevant, Girotra
et al. (2007) point out that the marginal value of a project is smaller for pharmaceutical firms with
large project portfolios for at least two reasons. The chances to successfully release a drug for a
given market (indication) increase in the number of alternative drug candidates for this market in
a firm’s development pipeline. The value of a given project hence decreases in the number of al-
ternative candidates. Consequently, the likelihood that a project is abandoned as consequence of a
loss of exclusivity should be higher for large firms compared to small firms. Additionally, conduct-
ing clinical trials requires firms to hold available relevant resources, such as clinical trial sites and
bio-statisticians. It is costly to scale the capacity of these resources up or down as they resemble
fixed assets (Girotra et al., 2007). Firms with a larger pipeline of projects can be expected to be
more willing to abandon a project in case it frees up the constrained resources for another pipeline
development project. Contrary, firms with a thin project pipeline might be more likely to hold on
to projects in order to avoid fixed assets being underutilized. Thus, we expect the negative effect of
a loss of exclusivity on the likelihood of successful drug commercialization and continuation to be
more pronounced for firms with large development pipelines.
3 Research design, data and variables
3.1 Research design
We study how the duration of market exclusivity is related to innovation incentives in the pharma-
ceutical industry. Linking development histories of drug projects with associated IP rights allows
us to identify how variation in the duration of market exclusivity periods affect companies’ innova-
tion efforts. We use a project’s successful completion of different stages in the development funnel
(pre-clinical, phase I, II, and III trials) and the eventual marketing authorization as key indicators of
innovation outcome. Simply linking the outcomes of drug development processes to expected peri-
ods of market exclusivity, however, will be plagued by selection biases. To overcome this challenge,
we exploit a natural experiment created by post-grant validity challenges: Conditional on one of the
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patents associated to a drug candidate being opposed at the EPO, we observe development projects
being at risk of patent invalidation and hence a reduction of the duration of the market exclusivity
period. Patent invalidation thus constitutes our treatment – projects affected by the loss of patent
protection and consequently a loss of exclusivity. Cases in which the opposed patents are upheld, on
the other hand, do not endure a loss of exclusivity and hence provide us with a control group. We
focus on projects where the opposition outcome has been communicated before the termination of
the development project (either abandonment by the company or approval of the drug). This makes
comparison of development outcomes of projects in the treatment group with those of projects in
the control group possible and identifies how variation in the duration of market exclusivity affects
project outcomes.
This approach has two caveats, however. First, our treatment (patent invalidation) might not
be exogenous but determined by unobservables that affect the likelihood of being treated as well as
the incentives to complete drug development. We address potential endogeneity in an instrumental
variables approach, which is discussed in detail in Section 5.1. Second, focusing on opposition
proceedings at the EPO implies that we observe a loss of exclusivity only for Europeanmarkets, while
a new drug might be marketed globally. As a consequence, our effect sizes need to be interpreted as
a lower bound of the “real” effect of a reduction of the duration of market exclusivity. If the loss of
exclusivity occurred in all markets uniformly, its effect would be more pronounced. We have argued
in Section 2.3 that patent invalidation at the EPO is likely to be correlated with a weakening of the IP
position in other jurisdictions. These cross-jurisdictional spillovers will reduce the extent to which
we underestimate the full effect.
3.2 Data sources
We collect data on drug development histories at the drug-indication level and link it to the under-
lying IP protection. Linking drug development projects to patents represents a non-trivial endeavor
(WIPO, 2014). Some jurisdictions have introduced regulations enforcing publication of patents
linked to marketed pharmaceutical products (Bouchard et al., 2010). These publicly available
patent-drug databases, such as the Orange Book or the DrugBank database, however, are restricted
to approved drugs. Yet, our study requires additional information on patents related to drug candi-
dates which have not gained approval and on patents that have been invalidated prior to a drug’s
market approval. We therefore draw on a commercial database, i.e., Clarivate’s Cortellis database
(March 2018), that provides curated information on patent-drug relationships such as associated
patents’ priority filings and their classification in primary and secondary patents.16 We augment this
data with further patent indicators extracted from EPO’s PATSTAT database.
Cortellis reports for each development project whether and when a particular development stage
(and ultimately marketing authorization) was reached. We rely on Cortellis’ information on discon-
tinuation of drug development to distinguish truncation from actual project termination at a given
16Cortellis has been used before in a similar fashion in Krieger (2017) and Krieger et al. (2018).
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development stage.17 Based on this information, we exclude pending development projects from our
analyses. Our research design requires that we restrict the analysis to drug development projects
that are linked to at least one opposed EP patent. Moreover, the decision on the opposition case
must fall between the start of drug development (discovery) and its completion (either drug ap-
proval or abandonment). Consequently, we construct the final sample as follows: first, we identify
all non-pending drug development projects at the drug-indication level in the Cortellis universe that
are associated with at least one EP patent that has been challenged in opposition proceedings. In a
second step, we remove drug-indication observations where the decision on opposition succeeded
the end of drug development.
In total, we are able to identify 1,769 unique drugs or drug candidates for which at least one
of the associated EP patents has been challenged in opposition proceedings. As Cortellis contains
information whether a drug is commercialized for one indication exclusively or whether it is ad-
dressing multiple indications we are able to construct development histories at the drug-indication
level. The 1,769 drug candidates for which at least one underlying patent has been opposed at the
EPO correspond to 6,442 unique development histories at drug-indication level. For 2,788 of these
observations (920 at drug level), the opposition outcome was published while the drug development
was ongoing; our analysis focuses on these cases.
3.3 Variables
Dependent variable
We observe whether a drug has passed major milestones of the drug development process at the
drug-indication level. These milestones are the successful completion of pre-clinical trials, phase I,
II, and III clinical trials as well as final marketing authorization. Based on this information we create
two indicator variables. The first indicator (approval) equals one if a drug reaches market approval
in Europe, US or Japan and zero otherwise.18 The second indicator (next stage) captures whether a
development project enters the next development stage after the opposition case has been decided.
For instance, if an opposition case is decided while a drug candidate is in clinical trials phase I, next
stage is equal to one if the drug candidate enters clinical trials phase II and zero otherwise.
Independent variables
Opposition outcome
Opposition at the EPO leads to one of three outcomes: the opposed patent is declared valid
with no changes requested (valid), the opposed patent is upheld but its scope is narrowed (valid
17A small number of projects are never officially discontinued and remain with the label “no development
reported”. We consider projects labeled as “no development reported” abandoned only if the last status update
occurred in 2013 or earlier. Our results are robust to earlier cut-offs.
18Market approval can be granted at national level or across the European Union by the European
Medicines Agency (EMA). Market approval by the EMA has become the predominant route since the har-
monization of data exclusivity terms in 2005.
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in amended form), or the opposed patent is declared invalid (invalid). In line with prior literature
(cf. Galasso and Schankerman, 2015; Gaessler et al., 2017), we interpret valid in amended form
as a substantial weakening of a patent’s strength and therefore pool it with the outcome invalid.
The indicator variable invalid is equal to one if the patent has been invalidated or amended in
opposition and zero otherwise.19
Loss of exclusivity
We compute the loss of exclusivity (LoE) due to patent invalidation as the difference between the
remaining patent term at drug approval and the duration of data exclusivity (see Section 2, Figure
2). LoE therefore is a function of development time (defined as the time lapsed between the date of
patent application (datePatApp) and the date of market approval of the drug (dateApproval)) as well as
the duration of data exclusivity (durDataExcl) with:
LoE=max [(Remaining patent term− durDataExcl) ; 0]
=max
 
20 years−
 
dateApproval − datePatApp

− durDataExcl

; 0

.
Note that SPC protection – if granted – increases LoE by up to five years. We calculate SPC
protection for all drug-indication cases and adjust our measure of LoE accordingly.20 Note further
that LoE is fully determined only once the date of market approval of a drug is known. Our sample is
restricted to cases, however, where opposition (and potential patent invalidation) takes place before
a drug’s approval, which renders the exact date of drug approval unknown. For this reason, we
predict a drug’s expected date of approval ( ÛdateApproval) at the time of patent invalidation. We derive
these estimates from median development times in a given indication of the Cortellis clinical trials
universe of all drugs.21 In order to maintain as much project-level variation for our observations as
possible, we employ a recursive procedure. First, we compute median durations of each phase of
drug development in a given indication (pre-clinical, phase I, II, and III). Second, actual development
times for observations in our final sample are added to the population median of the duration of
subsequent stages till approval (their actual duration is unknown at the time of the communication
of the opposition outcome).
Based on this estimate of the time of drug approval, we approximate a firm’s expectation regard-
ing the loss of exclusivity simply as the difference between the expected remaining patent term at
19The decision of the opposition division can be subject to appeal. However, the reversal rate of the boards
of appeal is low and we focus on opposition outcomes exclusively.
20The grant of SPC protection is product-as well as patent-specific (European Commission, 2018). To keep
things tractable, we assume possible SPC protection for each drug project unless the first drug-indication
project gained market approval before the time of opposition outcome.
21Figure A-1 in the Appendix illustrates the distribution of clinical trials lengths. We uniformly add 4 years
for the pre-clinical phase and another 12 months for registration after completion of phase III clinical trials.
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drug approval and the length of the exclusivity period,22 i.e.,
LoE=max

20 years−
 ÛdateApproval − datePatApp− durDataExcl ; 0 .
We compute this measure for all patents in our sample irrespective of subsequent invalidation.23
Strictly speaking, it is a measure of the potential loss of exclusivity. Only patent invalidation renders
the potential loss an actual loss, which we model using an interaction term between the invalidation
indicator and the loss of exclusivity measure. Figure 3 shows the distribution of (potential) loss of
exclusivity. In about 45% of all cases in our sample patent invalidation does not reduce the duration
of market exclusivity for the focal drug project; in these cases, the remaining patent term at expected
market approval is less than or equal to the duration of data exclusivity.24 The ratio of potential loss
of exclusivity to realized loss of exclusivity is fairly stable along the distribution, which opens up
the possibility to implement the loss of exclusivity as a linear treatment variable in the empirical
analysis.
Drug and drug development characteristics
We distinguish between drugs on a chemical and a biological basis. In contrast to chemical
drugs, biologics are derived from large molecules with therapeutic effect. We account for poten-
tial differences in drug development by introducing a biologics indicator variable equaling one for
biologics and zero otherwise based on Cortellis’ classification.25
About 30% of all drugs in Cortellis list development projects for multiple therapeutic indica-
tions. These indications refer to conditions or diseases that may significantly differ in prevalence,
clinical trial costs, and the likelihood of regulatory approval. To account for this heterogeneity,
we map Cortellis indications to their International Statistical Classification of Diseases and Related
Health Problems ICD-9 condition codes and add a set of Disease fixed effects based on aggregate
ICD-9 levels.26 It should be noted that while later-stage clinical trials are conducted separately for
different indications, results from pre-clinical trials and phase I clinical trials can – under certain
circumstances – be used across multiple indications, saving development cost. We construct a count
variable of the number of indications per drug and include it in our analyses and create a variable
indicating whether at the time of opposition outcome the drug has been already approved for another
22As elaborated in Section 2, data exclusivity was extended from six years (as the lower bound) to ten
years in Europe. We assign 10 years of data exclusivity to all cases that had the expected date of approval in
November 2005 or later and where patent invalidation occurred after the announcement of the policy change
in May 2004.
23There is reasonable concern that the used drug development times are not fully exogenous. First, the
observed order of development projects (at indication level) for the same drug is not random but a strategic
choice. Second, trial durations are partly calculated upon averages of the population, even though they can
be influenced by the originator. However, if more promising projects are sped up and prioritized, the actual
loss of exclusivity will be larger, which ultimately makes the estimated effect size a lower bound.
24Opponents might have an incentive to challenge granted patents at the EPO in the absence of a loss of
exclusivity to the originator company if an invalidation at the EPO improves their legal position in subsequent
litigation cases in other jurisdictions.
25Unlike in the US, data exclusivity regulations in Europe do not discriminate between chemical drugs and
biologics.
26The used concordance table has been introduced by Krieger (2017).
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Figure 3: Distribution of loss of exclusivity
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Notes: This figure shows the distribution of potential and realized loss of exclusivity (in years). Observations are at the drug-indication
level with the largest (potential) loss of exclusivity in the sample.
therapeutic indication than the one of the focal observation.
A drug’s development stage at opposition outcome is captured by a set of indicator variables
reflecting whether the opposition was decided during pre-clinical trials, phase I, II, or III clinical
trials.27 We further include the duration between drug discovery and opposition outcome in order to
control for heterogeneity in the speed of trial completion.
Originator characteristics
Originators differ across various dimensions with potential implications for their drug de-
velopment activities (Arora et al., 2009; Dranove et al., 2014) and their behavior in opposition
proceedings (Harhoff and Reitzig, 2004; Harhoff et al., 2016). Most importantly, we construct a
size classification based on the number of parallel development projects a company is involved in
at the time of the opposition outcome. Originators are categorized as small if they are involved in
fewer than the median of development projects (i.e., 30) and large if involved in more. In addition,
we distinguish originators as being corporate entity or not (e.g., universities) and based on their
place of incorporation (European vs. non-European) and include dummy variables in the regressions.
Opponent characteristics
Characteristics of the opposing party may also affect opposition outcomes. We therefore control
for whether the opponent is a corporate entity or not and its place of incorporation (Europe or
27The pre-clinical phase serves as reference group.
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not). Oppositions can be filed by multiple independent parties. We include a variable capturing
the number of opponents. In case of multiple opponents, we set the respective indicator to one if at
least one party is a corporate entity or European.
Patent characteristics
Drugs typically are surrounded by more than one patent that form a “patent fence”. We opera-
tionalize the patent fence simply as the total number of patents linked to a particular drug as stated
in the Cortellis database.28 We are further able to distinguish primary patents linked to a drug from
secondary patents.29
Moreover, we seek to characterize heterogeneity regarding patent protection of drugs by using
correlates to a patent’s value and its characteristics. Regarding patent value, we focus on measures
that are independent of the examination and opposition proceeding at the EPO. Our regressions
include a dummy variable for international patent applications (PCT), a count variable for DOCDB
patent family size, and the number of forward citations within the first three years after filing.30 In
order to further characterize a patent beyond these value indicators, we include a count of different
IPC4 subclasses, the number of independent claims, the number of inventors, the number of references
to patent documents and the number of references to non-patent literature. We also account for the
time between filing and examination, the duration of the examination itself, as well as the place and
the language of the examination procedure. Finally, we add technology field fixed effects based on the
OST/ISI concordance table (Schmoch, 2008) and fixed effects for patent age at opposition, the year
of patent grant and the year of opposition decision.
4 Descriptive statistics
4.1 Sample composition
Drug-level statistics
In total, the Cortellis database contains information on 44,764 unique drug candidates with non-
truncated development information (column 1, Table 1). About one third (14,149) of these ob-
servations are linked to at least one EP patent (column 2, Table 1), including 1,769 unique drug
candidates with at least one of the underlying EP patents having been challenged in opposition pro-
ceedings at the EPO (column 3, Table 1). In order to identify the effect of patent invalidation on
drug development, we require the decision on the opposition case to be communicated before drug
approval (or project termination), which reduces our sample further to 920 unique drug candidates
(column 4, Table 1).
28We avoid potential endogeneity and restrict the patent count to patents that had been filed before the
opposition outcome was communicated.
29Figure A-2 in the Appendix shows the distribution of patent-drug relationships by opposition outcome.
30A discussion of these indicators can be found in Wagner and Wakeman (2016).
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Table 1: Drug characteristics
(1) (2) (3) (4)
All drugs All drugs All drugs All drugs
with patent link with opposition in oppo. sample
N = 44,764 N = 14,149 N = 1,769 N = 920
Drug level Mean Mean Mean Mean
Drug characteristics
Biologic (d) 0.31 0.33 0.40 0.44
Drug discovery (yr) 2003.04 2000.51 1996.03 1996.86
Latest development (yr) 2008.43 2009.33 2008.38 2011.16
Approval in at least one indication (d) 0.06 0.17 0.57 0.58
# Indications 1.53 2.01 3.46 4.61
# Indications (in opposition sample) 3.03
Patent protection
# Patent families 3.74 15.35 18.84
# Opposed patents 2.51 3.09
# Invalidated patents 1.85 2.33
Notes: Observations are at the drug level. “All drugs” refers to all non-pending drug projects with development information in Cortellis.
“All drugs with patent link” refers to the subset of non-pending drug projects with a link to a patent family containing at least one EP
patent. “All drugs with at least one opposition” refers to the subset all non-pending drug projects with at least one EP patent challenged
in opposition proceedings. “All drugs in opposition sample” refers to all non-pending drug projects that are part of our final sample of
analysis. Patent families follow the INPADOC patent family definition.
Table 1 presents summary statistics of selected drug and patent characteristics for the different
subsamples of the Cortellis data and shows that the final sample is likely skewed towards high-
value drugs. The number of different patent families associated with a drug is an indicator of a
drug’s value as it is related to a company’s costly effort to create a strong IP position surrounding a
drug (“patent fence”) to minimize the risk of imitation. Drugs associated with at least one opposed
patent are surrounded by an average of 15.35 different patent families and drugs in our final sample
(opposition decision prior to project termination) by 18.84 different patent families; see columns 3
and 4 of Table 1. Compared to an average of only 3.74 patent families for all projects with known
patent link, these numbers are significantly higher and indicate that opposition is associated with
higher value drugs. Similarly, the share of drugs with approval for at least one indication is about
58% in the final sample but only 17% for all drugs with a patent link. Finally, drugs with opposed
patents have been tested against 3.46 different indications on average compared to 2.01 indications
for drugs with known patent link.31 These differences are partly driven by cohort effects, as drugs
associated with opposed patents are on average older in terms of discovery year. However, value may
31Drugs in our final sample have been tested against 4.61 different indications. Note that we exclude
development histories where the opposition outcome occurs before project start or after its termination. The
final sample therefore contains only an average of 3.03 indications per drug.
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also constitute an important additional determinant of differences in observed patent characteristics
and selection into opposition. Existing literature argues that patents attached to valuable projects
are significantly more likely to be challenged. The selection towards more valuable projects renders
our results conservative. Given that companies put more effort into developing higher value projects,
any negative relation between patent invalidation and project progress in our sample underestimates
the unknown population effect.
Drug-indication level statistics
A given drug’s efficacy is typically tested against multiple indications independently. In total, Cortel-
lis contains 75,396 different non-pending drug-indication level projects (each of the different 44,764
drug candidates is associated with an average of 1.68 different indications) out of which about 6%
are approved for the market while 94% are terminated before approval. Attrition patterns differ
by sample definition (see Figure A-4 in the Appendix). The majority of cases (62%) of all drug-
indication level projects are terminated after the pre-clinical phase before major investments in
clinical trials are due. Development projects with patent link are characterized by higher approval
rates (17%) and terminated at later stages compared to the population of non-pending projects. The
projects in our final sample (projects associated with opposed patents where a decision on opposi-
tion was communicated before termination) follow a similar pattern of comparably late termination
and average approval rates of 30%.
4.2 Patent invalidation and development outcomes
We present descriptive evidence on how patent invalidation in opposition proceedings affects drug
development outcomes. In Figure 4, we report attrition rates at the drug-indication level and dis-
tinguish between cases with no patent invalidated in opposition and cases with at least one patent
invalidated in opposition. We find notable differences between these two groups. First, projects
with at least one patent invalidation before project termination lead to final drug approval in 29%
of cases. In contrast, if no patent was invalidated, average approval rates are significantly higher
with 36%. This descriptive evidence is in line with our prediction that patent invalidation reduces
approval rates as the incentive to engage in costly development efforts is diminished.
To further explore how the exact timing of the opposition outcome affects project success, we
report the advancement through the development funnel for all projects in our final sample by a
drug’s development stage at time of opposition outcome in Figure 5a. Patent invalidation does
not only lower the likelihood drug approval but also the likelihood of initiating the next stage of
the development process. As expected, early patent invalidation has a stronger negative effect on
a drug’s progress. While this clearly holds for drug approvals, its relation to continuations is not
clearly visible in this bivariate graph. Figure 5b breaks down approval and continuation by firm size
(small vs. large originators). Drug invalidation lowers the likelihood of approval and continuation
for small and large originators.
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Figure 4: Project advancement at the drug-indication level by opposition outcome
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Notes: Observations are at the drug-indication level. “All drugs in final sample” refers to all non-pending drug projects that are part of
our final sample of analysis.
Figure 5: Project advancement at the drug-indication level
(a) By development stage
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Notes: This figure presents progression of drug projects (drug-indication level) conditional on their development stage at time of oppo-
sition outcome for the regression sample.
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Table 2: Highest development stage by development stage at time of opposition outcome
Development stage
at opposition
outcome
Development stage reached
Pre-clinical Phase 1 Phase 2 Phase 3 Approval
No patent invalidated
Total 329 −−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−→ 120 36.5%
Pre-clinical 168 (67.9%) 114 101 80 70 41.7%
Phase I – 31 (29.0%) 9 7 6 19.4%
Phase II – – 63 (19.0%) 12 7 11.1%
Phase III – – – 67 (52.7%) 37 55.2%
At least one patent invalidated
Total 2,459 −−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−→ 725 29.5%
Pre-clinical 1,446 (72.8%) 1,052 946 601 452 31.3%
Phase I – 168 (32.7%) 55 36 31 18.5%
Phase II – – 498 (18.7%) 93 55 11.0%
Phase III – – – 347 (53.9%) 187 53.9%
Notes: This table presents progression of projects (drug-indication level) conditional on their development stage at time of opposition
outcome for the regression sample. Percentages are conditional on having reached the prior development stage.
Finally, we report the advancement through the development funnel for all projects in our final
sample (drug-indication level) in a life-table-like fashion. Table 2 tabulates the development stage
in which opposition was decided (rows) against the subsequent stages reached by the respective
development projects (columns).32 In total, our final sample contains 329 development projects
where no underlying patent has been invalidated before project termination or approval with 120
(36.5%) of these cases leading to final approval in a given indication (first line of Table 2). For a
subset of 168 projects, the opposition outcome “valid” was communicated while the drug was still
in pre-clinical trials. The second line of Table 2 reports how these 168 projects advance through the
development funnel with 70 projects (41.7%) eventually being approved. Additionally, we report
the number and share of projects that start the next stage after communication of the opposition
outcome – in this case 114 projects (67.9%).
Table 2 further reveals differences in progress patterns for projects by opposition outcome. While
early patent invalidations during pre-clinical trials have no different effect on the likelihood of taking
the drug to the next stage, final approval rates of 29.5% are significantly lower compared to 36.5%
for cases where patents are upheld. Moreover, oppositions leading to patent invalidation only during
clinical trials are associated with lower drug approval rates as well as lower probabilities of starting
32Due to the life-table logic, the left-most number in each row of Table 2 denotes the overall number of
projects for which the opposition proceeding has been decided in a given stage. Moving right in a given row
lists how many projects survive the transition to the subsequent stage in the development funnel.
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the next development stage. These differences are more pronounced during phase I and phase II
but remain present in phase III. One explanation is that once phase III trials have been initiated, the
additional investments needed for market approval are lower than in situations in which invalidation
is communicated before the start of phase III trials.
5 Multivariate analysis
5.1 Identification
Estimation approach
In our multivariate analyses we relate measures of IP protection, most importantly the loss of exclu-
sivity after patent invalidation in opposition proceedings, to measures of drug development success;
approval indicates whether the drug candidate reached marketing authorization; next stage indicates
whether a drug candidate entered the next development stage after the opposition case was decided.
We estimate linear probability models at the drug-indication level to identify the effect of a loss of
exclusivity due to patent invalidation on development success. Our main empirical specification is:
Approval = γ (Invalidation× LoE) +
+ β0 + β1 Invalidation + β2 LoE+ β3 X + ε.
The interaction between Invalidation and LoE identifies cases in which a patent invalidation
(Invalidation = 1) leads to an actual loss of exclusivity. The coefficient γ captures the effect of a
realized loss of exclusivity LoE (treatment effect) on the likelihood that a drug candidate will be
approved for marketing or advances to the next stage of clinical trials after the opposition case has
been resolved. If γ < 0, a reduction of the period of market exclusivity lowers the chances of drug
approval. A finding of γ= 0 would indicate that the period of market exclusivity does not affect drug
approval. To control for heterogeneity in the underlying drug development projects, originators and
patents, we include a set of additional independent variables X in our regressions.33
We include development projects multiple times in the estimations to account for cases with
more than one opposed patent per drug-indication development project. Each observation per drug-
indication project is weighted by the inverse of the number of associated patents. Since drug candi-
dates can be involved in separate development histories for different indications, we report two-way
clustered standard errors at the drug as well as at the indication level.
Instrumenting patent invalidation
The major empirical challenge is that patent invalidation is likely to be endogenous as the outcome
of the opposition procedure might be determined by unobservable characteristics (such as early
33A comprehensive list of the control variables can be found in Table B-1 in the Appendix.
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signs of a drug’s efficacy or potential market size) that affect (i) the effort put into defending the
patent as well as (ii) the incentives to commercialize a drug. Such a situation would generate a
positive correlation between ε and Invalidation in our regression equation and therefore bias the
OLS estimate of γ upwards. To address potential endogeneity of the outcome of the opposition
proceeding, we employ an instrumental variable that affects the likelihood of patent invalidation
but does not belong in the drug approval equation.
Following Gaessler et al. (2017), we use the granting patent examiner’s participation in the
opposition proceeding as the basis for instrumentation. Specifically, we instrument the opposition
outcome (Invalidation) as well as its interaction with LoE with the predicted probability of invalida-
tion obtained from a probit model Prob(Invalidated)
∧
= Φ(γ1Examiner participation+ γX). Note that
this estimator is asymptotically efficient in the class of estimators based on instruments being a func-
tion of examiner participation and other independent variables (Wooldridge, 2010). Furthermore,
if Prob(Invalidated)
∧
is a valid instrument for Invalidation, then Prob(Invalidated)
∧
× LoE is a valid
instrument for Invalidation × LoE. Based on this reasoning we estimate the following two-stage
model:
Invalidation = α Prob(Invalidated)
∧
+ θ X + u
Approval = γ (Invalidation× LoE) +
+ β0 + β1 Invalidation
∧
+ β2 LoE+ β3 X + ε.
Our instrument exploits variation in the participation of the patent examiner who initially
granted the patent in the opposition division. Although the rules and regulations of the EPO al-
low some personnel overlap in the examination and opposition procedure, they do not require the
involvement of the initial patent examiner in the opposition division. In fact, the average examiner
participation rate is about 68% across all opposition proceedings at EPO, with continuous variation
over time and technology fields. The variation in examiner participation has been described as a re-
sult of the temporary non-availability of other examiners with expertise in the particular technology
area and can be considered random to the focal patent (Gaessler et al., 2017). Figure A-3 in the
Appendix presents the annual number of opposition proceedings and the annual rate of examiner
participation.
Gaessler et al. (2017) discuss the instrument’s randomness and relevant exclusion restrictions in
detail. Most importantly, indicators of patent value, the length of the initial examination of the patent
applications and characteristics of the patent holder as well as the opponent do not significantly
affect the likelihood of the initial examiner’s participation in the opposition proceeding. This finding
is in line with views expressed by EPO officials and patent attorneys that the participation of the
examiner is independent of the opposed patent and beyond the influence of the patent holder or the
opponent. The exclusion restriction of the instrument prevails given that the patent holder (in our
context, the originator company) is unlikely to foresee the examiner’s participation for two reasons.
First, participation rates calculated at examiner level show little concentration at zero and one, but
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Table 3: 1st-stage regression: Examiner participation and opposition outcome
(1) (2) (3)
Estimation method Probit Probit Probit
Dep var Invalidated Invalidated Examin. partic.
Exam. participation (d) −0.051∗∗ −0.055∗∗∗
(0.021) (0.018)
Potential LoE (in yrs) 0.000
(0.005)
Drug characteristics No Yes∗∗∗ Yes∗
Development characteristics No Yes∗ Yes
Patent characteristics No Yes∗∗∗ Yes∗∗∗
Technology effects No Yes∗∗∗ Yes∗∗∗
Disease effects No Yes∗∗∗ Yes∗∗∗
Examination characteristics No Yes Yes
Age effects No Yes Yes∗
Originator characteristics No Yes∗∗ Yes
Opponent characteristics No Yes∗∗∗ Yes
Year effects No Yes∗∗∗ Yes∗∗∗
Model degrees of freedom 1 112 110
χ2-statistic 5.8 479.0 299.8
Pseudo-R2 0.004 0.197 0.129
Observations 5,959 5,959 5,936
Observations (weighted) 903 903 903
Notes: The probit regressions in columns (1) and (2) highlight the relevance of the Examiner participation dummy for the outcome
of the opposition proceeding. The invalidation predictions of the probit regression in column (2) are used as instrument in the 2SLS
instrumental variables regressions throughout the remainder of the paper. Column (3) shows the probit regressions of the Examiner
participation dummy on our main independent variables of interest while controlling for other variables. A comprehensive list of the
control variables contained in the indicated groups can be found in Table B-1 in the Appendix. 23 observations dropped due to perfect
prediction in column (3) and (4). Marginal effects are reported in all columns. Standard errors are clustered by patent. Observations
are weighted by the inverse of the number of different drug projects per patent. Significance levels: * p<0.1, ** p<0.05, *** p<0.01.
rather follow a normal distribution around the overall participation rate (as shown in Gaessler et al.
(2017)). Second, the opposition division members are disclosed only during the oral proceeding,
which typically results in a final decision on the opposition case. Hence, neither applicant nor
opponent has time to adjust their strategy during the opposition proceeding.
Table 3 presents the results from probit regressions relating examiner participation to opposition
outcomes controlling for other sources of heterogeneity. The dependent variable is at the patent level
and patents might be associated with more than one development project if the associated drug
is tested against multiple indications. For this reason, we include all observed patent-indication
observations in the regressions and employ weighted estimators in which we use the inverse of the
number of drug indications per patent as weights and report standard errors clustered at the level of
individual patents. In total, these regressions are based on 903 unique patents that are associated
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with an average of 3.01 different indications resulting in 2,719 observations at drug-indication level
and 5,959 observations at drug-indication patent level.34 Examiner participation is negatively and
highly significantly related to patent invalidation in opposition proceedings even after controlling
for a comprehensive set of other factors (see Table 3, column 2). Opposition divisions are less
likely to invalidate a patent if the initial examiner participates. As can be seen from column 3,
examiner participation is not only orthogonal to our key explanatory variable Potential LoE, but also
to various other aspects of the opposition proceeding, including characteristics of the drug, the drug
development process, the originator or the opponent.
Assumptions for identification
A key assumption of our identification strategy is that patent validity is independent of a drug
project’s probability of success. There are two potential concerns arguing against this assumption.
First, patent validity may be directly affected by the virtue of a drug. In line with Roin (2008), we ar-
gue that patentability is hardly related to a drug’s (social) value and its chance of market approval.35
Irrespective of this, our instrumental variable estimations would assure identification even if (unob-
servable) patent characteristics correlated with the drug’s likelihood of market approval. Second,
patent validity (or the existence of patent protection in general) might be taken into account by
authorities that decide on a drug’s market approval. However, legal regulations prevent any form
of “patent linkage” of drug approval. In Europe, the marketing authorization decision needs to be
exclusively based on scientific criteria related to public health considerations – most importantly
toxicology and efficacy characteristics of a drug candidate – while other criteria such as patent pro-
tection are not considered (European Commission, 2009). Patent validity hence can be seen as
independent of a drug candidate’s likelihood of success in terms of market approval.
5.2 Results
Before discussing the results from our regressions in detail, we provide an overview of the main
findings. First, our findings indicate that an increase in the loss of exclusivity leads to a significant
reduction of the likelihood of drug approval and continuation. Second, taking the timing of patent
invalidation into account, we find that a loss of exclusivity at an early stage of product development
has a more significant negative effect on commercialization outcomes compared to later stages.
Third, splitting our sample between small/medium and large originator companies, we find evidence
for differential effects of patent invalidation by firm size. Large originators are considerably more
likely to abandon projects after a reduction in the expected duration of market exclusivity. These
findings are robust to various subsamples and alternative operationalizations of the dependent as
34The small difference to the overall sample is due to perfect prediction of the first stage outcome.
35In fact, patent invalidation in opposition proceedings at the EPO may result from a lack of novelty,
insufficient inventive step, insufficient disclosure of the invention or the undue broadening of the patent
scope beyond the initial application. These criteria are not related to a drug’s efficacy and toxicology which
ultimately determine its value.
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well as the key independent variables (see Section 5.3). We discuss these findings in detail below.
Main specification
In Table 4, we report results from regressions relating loss of exclusivity due to patent invalidation
to market approval and the starting of the next stage in the development process using linear prob-
ability models as well as linear IV estimators in which we instrument patent invalidation and its
interaction term. In columns 1, 2 (approval) and 5, 6 (next stage) of Table 4, we do not account
for the loss of exclusivity but focus merely on the effect of patent invalidation. The OLS and IV
estimate of the effect of patent invalidation on drug approval is statistically indistinguishable from
zero both for approval as well as next stage. The coefficients of patent invalidation, however, do not
relate to the resulting loss of exclusivity and that – in case of patent invalidation – the implied loss of
exclusivity varies considerably across projects. In cases where the remaining patent term at market
approval is lower than the period of data exclusivity, the duration of a drug’s market exclusivity is
entirely determined by data exclusivity and patent invalidation does not degrade the legal position
of the originator company. The estimated coefficients of patent invalidation presented in columns
1, 2, 5, and 6 of Table 4 therefore do not reflect a loss of exclusivity, which likely explains the high
standard errors of the coefficient estimates.
In order to quantify how a loss of exclusivity affects the likelihood of successful drug commercial-
ization, we include the potential loss of exclusivity measured in years (LoE) and its interaction with
patent invalidation in the regressions (Table 4, columns 3 and 4 as well as columns 7 and 8). Across
all specifications, the IV estimates point to a stronger and more precisely estimated effect negative
effect of the interaction term compared to the OLS specifications. This difference is likely driven by
unobserved variables (such as early signs of efficacy or commercial attractiveness of an indication)
that affect patent invalidation (as a function of opponent effort) and drug approval, resulting in an
upward biased OLS estimate. The results from the IV regression suggest that a one-year reduction of
expected market exclusivity reduces the likelihood of drug approval by 3.5 percentage points (Table
4, column 4). This an economically meaningful effect given that the average likelihood of successful
drug commercialization in our sample is 30.5% and the average market exclusivity length is about
10 years.36
The results regarding the likelihood of project continuation are comparable. Loss of exclusivity
induced by patent invalidation significantly lowers the likelihood of project continuation with more
pronounced and more precisely estimated effects in the IV specifications. The results reported in
column (8) of Table 4 imply that a one-year reduction in the expected market exclusivity of a new
drug leads to an average decrease in the likelihood of project continuation of 4.7 percentage points.
Compared to an average continuation rate of 50.7% across all development stages, this again is an
economically meaningful effect and suggests that firms immediately respond to a change in market
exclusivity. Taken together, we consider this strong evidence for the originator’s reduction of com-
36Note that the potential loss of market exclusivity, as a strong correlate of the overall length of market
exclusivity, positively affects drug approval.
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mercialization efforts in response to ceteris paribus lower expected profits due to a shorter duration
of the market exclusivity period. Figure 6 shows binned scatter plots of the residuals for two of our
regressions (column 4 and column 8 in Table 4, respectively). These figures confirm the linearity of
the effect of the realized market exclusivity loss on drug development outcomes.
All regression specifications include a comprehensive set of control variables capturing char-
acteristics of the drug, the development project, the originator, the opponent, and the underlying
patent, as well as time and disease fixed effects. We do not report coefficients for these variables
but briefly comment on the most important findings here. While drug characteristics are jointly
significant in our regressions, individual variables have little explanatory power. In particular, our
findings suggest that biologics are not characterized by different approval rates. Regarding patent
indicators, we find that development projects associated with patents of higher value (as indicated
by patent family size) have a higher likelihood of approval. This finding is in line with Wagner and
Wakeman (2016), who attribute these differences to applicants creating stronger protection around
more promising drugs. With respect to originator characteristics, we find development projects of
small originators associated with lower approval rates compared to medium and large originators.
Figure 6: Effects of market exclusivity loss (in years) on drug development
(a) Drug approval
-.4
-.2
0
.2
Ch
an
ge
s in
 Ap
pro
va
l
0 2 4 6 8
Loss of exclusivity (in years)
No Yes       
Patent invalidated:
(b) Next stage
-.4
-.2
0
.2
Ch
an
ge
s in
 Ne
xt 
sta
ge
0 2 4 6 8
Loss of exclusivity (in years)
No Yes       
Patent invalidated:
Notes: These figures plot market exclusivity loss (in years) on the change in drug development outcome (approval or continuation of
drug development). The figure hereby distinguishes between cases where the patent was invalidated, so loss of exclusivity occurred,
and where the patent survived, so no loss of exclusivity occurred. To construct this binned scatterplot, we predict the residuals from the
estimated regressions in column 4 and column 8 in Table 4 and plot these by the instrumented variable Loss of exclusivity (in years).
Timing of invalidation
In this subsection, we report results from specifications that account for the timing of patent invali-
dation. We have argued above that originator companies face a sequential decision-making process
when developing new drugs. Early losses of exclusivity should have a more pronounced effect on
firm decision making. As argued before, this result can be explained by the sequential nature of
the (then sunk) investments in the different clinical trial stages (Dixit and Pindyck, 1994; Pindyck,
1991).
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In order to test the prediction regarding the timing of invalidation (early vs. late), we split the
sample in development projects with opposition decisions at an early stage (pre-clinical/phase I
trials) and at a late stage (phase II/phase III trials). About 64% of the projects in our final sample
had the opposition outcome of the underlying patent(s) during pre-clinical/phase I trials and 36%
at later stages. In columns 1 to 4 in Table 5, we report the effect of a loss of exclusivity due to
patent invalidation on drug approval and next stage based on this sample split. While the coefficient
on the interaction carries the expected negative sign across all specifications, only the effect of
early invalidation is significantly different from zero. A one-year loss of exclusivity due to patent
invalidation at an early stage of development reduces the likelihood of eventual drug approval by
4.6 percentage points and the likelihood of starting the next stage of clinical trials by about 6.1
percentage points, which are slightly larger effects compared to our baseline effects reported in
Table 4. A reduction in the exclusivity period affects firm behavior more significantly when received
early, i.e., at a stage of the development funnel where the majority of investments still have to
be committed. The fairly large standard errors for the estimates in the late stage subsample hint
at considerable heterogeneity in firm responses. This is probably due to the fact that some drug
projects in this subsample require little to now further investments to reach approval.
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Table 4: Impact of patent invalidation on drug development (baseline)
(1) (2) (3) (4) (5) (6) (7) (8)
Estimation method OLS IV OLS IV OLS IV OLS IV
Dep var Approval Next Stage
Dep var mean 0.305 0.305 0.305 0.305 0.507 0.507 0.507 0.507
Invalidated −0.018 −0.151 0.021 −0.076 0.011 −0.129 0.044 0.006
(0.030) (0.121) (0.031) (0.124) (0.034) (0.125) (0.039) (0.139)
Invalidated × Potential LoE (in yrs) −0.015∗ −0.035∗∗ −0.014∗ −0.047∗∗∗
(0.009) (0.017) (0.009) (0.015)
Potential LoE (in yrs) 0.037∗∗∗ 0.052∗∗∗ 0.000 0.025∗∗
(0.008) (0.013) (0.008) (0.012)
Drug characteristics Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗
Development characteristics Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗
Patent characteristics Yes∗∗ Yes∗∗ Yes∗∗ Yes∗∗ Yes∗∗ Yes∗∗ Yes∗∗ Yes∗∗∗
Technology effects Yes Yes∗ Yes Yes∗∗ Yes Yes Yes Yes
Disease effects Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗
Examination characteristics Yes Yes Yes Yes Yes Yes Yes Yes
Age effects Yes Yes∗∗ Yes Yes∗∗∗ Yes Yes Yes Yes
Originator characteristics Yes∗∗ Yes∗ Yes∗∗ Yes∗∗ Yes∗∗ Yes∗∗ Yes∗∗ Yes∗∗
Opponent characteristics Yes Yes Yes Yes Yes Yes Yes Yes
Year effects Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗
Underidentification test 36.5 33.9 36.5 33.9
Weak identification test 52.8 24.6 52.8 24.6
Observations 5,959 5,959 5,959 5,959 5,959 5,959 5,959 5,959
Observations (weighted) 2,719 2,719 2,719 2,719 2,719 2,719 2,719 2,719
Notes: Columns (1) and (2) as well as (5) and (6) provide a comparison between the OLS and the 2SLS regressions for the impact of invalidation on drug development (approval or continuation to next
stage) when accounting for the actual loss of exclusivity. Columns (3) and (4) as well (7) and (8) include an interaction term capturing the loss of exclusivity in linear form. In each 2SLS regression the
Invalidated dummy is instrumented with the corresponding probability predicted by a probit regression on the Examiner participation dummy and all other exogenous variables. The underidentification
and weak identification tests are the heteroskedasticity-robust Kleibergen and Paap (2006) rk LM and Wald F statistics, respectively, as reported by Stata’s ivreg2 command (Baum et al., 2010). A
comprehensive list of the control variables contained in the indicated groups can be found in Table B-1 in the Appendix. Standard errors are two-way clustered by drug and indication. Observations are
weighted by the inverse frequency at drug-indication-patent-level. Significance levels: * p<0.1, ** p<0.05, *** p<0.01.
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Table 5: Impact of patent invalidation on drug development by timing and portfolio size
(1) (2) (3) (4) (5) (6) (7) (8)
Dep var Approval Next Stage Approval Next Stage
Sample Pre-clinic/Phase I Phase II/III Pre-clinic/Phase I Phase II/III Small Large Small Large
Dep var mean 0.302 0.307 0.505 0.507 0.302 0.307 0.505 0.507
Invalidated −0.060 −0.068 0.071 −0.098 −0.268 −0.011 −0.221 0.142
(0.143) (0.193) (0.164) (0.216) (0.204) (0.190) (0.221) (0.205)
Invalidated × Potential LoE (in yrs) −0.046∗∗ −0.025 −0.061∗∗∗ −0.025 −0.007 −0.048∗∗ −0.026 −0.058∗∗∗
(0.018) (0.026) (0.018) (0.028) (0.025) (0.022) (0.032) (0.018)
Potential LoE (in yrs) 0.079∗∗∗ 0.003 0.041∗∗∗ −0.010 0.023 0.062∗∗∗ 0.003 0.033∗∗
(0.015) (0.022) (0.015) (0.023) (0.021) (0.017) (0.027) (0.014)
Drug characteristics Yes∗∗∗ Yes Yes∗∗∗ Yes Yes∗∗∗ Yes∗∗ Yes∗∗∗ Yes∗∗∗
Development characteristics Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗
Patent characteristics Yes∗∗∗ Yes Yes∗∗ Yes Yes∗∗ Yes∗ Yes∗∗ Yes∗∗∗
Technology effects Yes∗∗ Yes∗∗∗ Yes∗ Yes∗∗∗ Yes∗ Yes∗∗∗ Yes Yes∗∗∗
Disease effects Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗ Yes∗∗∗ Yes∗∗∗
Examination characteristics Yes∗∗ Yes Yes∗∗∗ Yes Yes Yes Yes Yes
Age effects Yes∗∗∗ Yes∗∗∗ Yes Yes∗∗∗ Yes∗∗ Yes∗∗∗ Yes Yes
Originator characteristics Yes∗∗ Yes Yes∗∗∗ Yes Yes∗∗∗ Yes Yes∗∗∗ Yes
Opponent characteristics Yes Yes Yes Yes Yes∗∗∗ Yes Yes∗∗ Yes
Year effects Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗
Underidentification test 28.2 20.6 28.2 20.6 14.3 22.6 14.3 22.6
Weak identification test 20.6 11.9 20.6 11.9 10.5 13.9 10.5 13.9
Observations 4,311 1,648 4,311 1,648 2,345 3,614 2,345 3,614
Observations (weighted) 1,757 962 1,757 962 1,076 1,643 1,076 1,643
Notes: Columns (1) to (4) show 2SLS regressions for the impact of invalidation on drug development on subsamples defined by the development stage of the drug project at the time of opposition
outcome. The samples used in columns (1) and (3) include drug projects only if the patent opposition outcome occurred during the pre-clinical phase or in clinical phase I. Likewise, the samples used
in columns (2) and (4) include drug projects only if the patent opposition outcome occurred during clinical phase II or III. Columns (5) to (8) show 2SLS regressions for the impact of invalidation on
drug development on subsamples defined by the size of the drug originator. The samples used in columns (5) and (6) include drug projects only if the drug originates from small entities. Likewise,
the samples used in columns (7) and (8) include drug projects only if the drug originates from large entities. In each 2SLS regression the Invalidated dummy is instrumented with the corresponding
probability predicted by a probit regression on the Examiner participation dummy and all other exogenous variables. The underidentification and weak identification tests are the heteroskedasticity-robust
Kleibergen and Paap (2006) rk LM and Wald F statistics, respectively, as reported by Stata’s ivreg2 command (Baum et al., 2010). A comprehensive list of the control variables contained in the indicated
groups can be found in Table B-1 in the Appendix. Standard errors are two-way clustered by drug and indication. Observations are weighted by the inverse frequency at drug-indication-patent-level.
Significance levels: * p<0.1, ** p<0.05, *** p<0.01.
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Originator size
Finally, we split our sample into small and large originators depending on the number of pending
development projects at the time of opposition outcome.37 About 38% of the projects are associated
with small orginators and 62% with large originators. In columns 5 to 8 of Table 5, we report the
effect of a loss of exclusivity due to patent invalidation on drug approval and next stage based on
this sample split. While overall the direction of the effect of the loss of exclusivity due to patent
invalidation is comparable to the baseline results in Table 4, we do find differences by originator
size. A realized loss of exclusivity has no significant effect on approval or continuation for small
originators (see columns 5 and 7 of Table 5). In contrast, projects of large originators are signif-
icantly affected by the realized loss of exclusivity. A one-year reduction in exclusivity lowers the
likelihood of drug approval by 4.8 percentage points and the likelihood of starting the next stage by
5.8 percentage points (see columns 6 and 8 of Table 5). We argue that portfolio considerations are
a likely explanation of the observed size differences.38 Large companies are more likely to drop a
project as they can reallocate their resources to alternative drug projects in their portfolio. In con-
trast, the marginal value for a given project is higher for firms with smaller portfolios (and hence
fewer outside options) (Girotra et al., 2007).39
Although not a central question of our paper, these insights also inform the ongoing debate to
what extent innovation incentives from IP rights are more important for small companies than for
large ones (Galasso and Schankerman, 2018). Galasso and Schankerman (2018) report that small
and medium sized companies significantly reduce their innovation efforts after patent invalidation,
whereas large firms are not affected. However, their study focuses on patenting activities in a five-
year time-window after patent invalidation as an indicator of innovative activities, while we focus on
a different aspect: Conditional on having started a development project, small/medium originators
are less likely than larger ones to reduce their innovation efforts after patent invalidation. In this
regard, our findings complement Galasso and Schankerman (2018), who focus on the start of new
projects, whereas we focus on the completion of existing projects.
5.3 Robustness tests and extensions
In order to assess the robustness of our findings, we estimate a number of alternative regression
specifications. To start, our results are not sensitive towards the choice of the regression model
applied. Employing biprobit models in order to account for the binary nature of the outcome variable
does not change our findings; in fact, the coefficients are estimated with higher precision. Equally,
results from unweighted regressions correspond well with the results reported above. Additionally,
37We split the sample at the median, which is 30 drug projects.
38In Table B-2 in the Appendix, we split up our sample by timing as well as the originator’s portfolio
size. The results correspond to our findings in the main text: the effect on drug commercialization is most
significant for the sample of large firms subject to patent invalidation in the early stages of the development
process.
39In line with this, Arora et al. (2009) find that large firms aremore selective when evaluating drug projects.
32
we investigate to what extent various institutional details of the drug development process affect
our results (see Figure 7 for an overview of these results).
Figure 7: Overview of robustness checks
Baseline result
Full sample
Robustness checks
First indication only
Primary patents only
Biologics only
EU approval only
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Approval
Next stage
Invalidated x Potential LoE(in years)  
Notes: This figure depicts the estimated coefficients of our main independent variable of interest, Invalidated× Potential LoE (in years), on
the dependent variable Approval, respectively Next stage. The regressions for the main results are reported in Table 4. The corresponding
regression tables for the robustness check results (in the Appendix) are the following: First indication only: Table B-3, Primary patents
only: Table B-4, EU approval only: Table B-5, Biologics only: Table B-6. Horizontal lines represent 95% confidence intervals. Dashed
vertical lines represent the baseline effects from the full sample.
First, we restrict our regressions to the first indication a drug candidate is tested against and
limit the sample to the first indication for each drug candidate. In these specifications, we rule out
the possibility that our findings are driven by originators’ decisions whether to reposition a drug
in additional indications depending on patent invalidation. Furthermore, the determination of ex-
pected market exclusivity is less ambiguous for first indication drug projects compared to subsequent
indications (see Section 2). Focusing on first indications exclusively, we observe slightly larger ef-
fects, though the precision of some estimates is lower due to a reduced sample size (see Table B-3
in the Appendix). Likewise, restricting the analyses to the primary patent underlying a drug leads
to results that compare well to the main findings reported above (see Table B-4 in the Appendix).40
Our main findings have been obtained by relating drug approval in Europe, US or Japan to
the loss of exclusivity incurred in Europe. Table B-5 reports the results where we focus exclusively
on drug approvals in Europe. Again, the results remain largely unchanged, though the effect is
smaller in magnitude and less precisely estimated. Furthermore, some jurisdictions have different
regulations for biological drugs when compared to traditional pharmaceuticals. For instance, in the
US biologics are subject to longer data exclusivity periods (12 years) than small molecule drugs (5
40For drugs with no opposed primary patent, we choose the patent with the largest patent family.
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years). As a result, market exclusivity lengths in Europe and US are more comparable for biologics.
We exploit this fact to address concerns that our effect sizes are potentially downward biased as we
calculate European market exclusivity periods, which may differ from those in other economically
relevant pharmaceutical markets. Table B-6 in the Appendix reports the findings of a reduced sample
containing development projects related to biological drugs exclusively. The effect of the realized
loss of exclusivity is highly significant and notably larger in magnitude than in our baseline model.
Finally, our key explanatory variable measures the reduction of the period of market exclusivity
in absolute terms (years). We replicate the main regressions in Table B-7 in the Appendix, but
measure the loss of exclusivity this time in relative terms, i.e., as one minus the fraction of the
reduced duration of market exclusivity after patent invalidation relative to the full duration. The
estimates correspond to our baseline findings but further gain in statistical significance.
6 Concluding remarks
This paper investigates the causal effect of the duration of market exclusivity on the likelihood of
successful product commercialization in the pharmaceutical industry. Patent invalidation due to
post-grant opposition at the EPO provides a natural experiment in which some drug development
projects are exposed to a shift in the expected duration of market exclusivity while others are not.
Instrumenting potentially endogenous opposition outcomes with the granting examiner’s participa-
tion in opposition proceedings allows for causal identification. Our regression results highlight that
a reduction in the expected duration of market exclusivity upon drug approval by one year signif-
icantly reduces the likelihood of drug approval in our sample by 3.5 percentage points relative to
a mean approval rate of 30.5%. Early exclusivity loss has a more significant impact than an exclu-
sivity loss at later stages. Moreover, the negative effect of a loss of exclusivity on the likelihood of
successful drug commercialization is driven by large originators whereas small originators seem less
responsive.
While the natural experiment underlying the analysis allows for the clean identification of causal
effects, our study is subject to some limitations. First, we observe outcomes for projects that have
already been initiated at the time when the duration of market exclusivity is unexpectedly reduced.
We therefore study firm responses at the intensive margin. Policy makers, in particular, might be
interested in understanding firm responses to regulatory changes at the extensive margin. We note
that firms can be expected to respond even stronger at the extensive margin as both uncertainty as
well as the necessary investments for successful commercialization are higher; our baseline effect
sizes therefore should be interpreted as lower bound. However, our estimates for the responses of
large firms with exclusivity loss in early stages of drug development provide an approximation of the
effect at the extensive margin. Large companies have broad pipelines of alternative drug candidates,
reducing the marginal value of any given project, in particular those in early stages. Second, our
evidence from the pharmaceutical industrymay not be generalizable to industries that are less reliant
on patents. Nonetheless, our study stands out from other studies on the pharmaceutical industry, as
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our estimates have been derived across a wide range of therapeutic areas. Finally, we leave aside
questions pertaining to strategic interactions between originators and do not examine the incentives
to challenge a granted patent in opposition proceedings. Future research may complement our
results by explicitly modeling competitive dynamics.
The effect of the duration of market exclusivity periods on the likelihood of drug approval has
important implications for scholars as well as policy makers concerned with the pharmaceutical
industry. It provides evidence that, as posited by the theoretical literature on the incentives for
innovation, R&D efforts of firms are muted in case of reduced periods of market exclusivity. Re-
cent research provides evidence that pharmaceutical companies target their R&D efforts to drugs
with shorter development times to enjoy longer periods of market exclusivity derived from longer
effective patent terms. This effect might induce socially inefficient allocation of private R&D expen-
ditures. Our findings suggest that data exclusivity can indeed be an effective policy lever to restore
incentives in case of long drug development periods, as it determines the duration of market exclu-
sivity periods in these cases. Extending data exclusivity periods as a policy instrument, however, is
not uncontested. It restricts access to drugs as companies enjoy longer periods in which they can
charge high prices. Additionally, extending data exclusivity periods might cause redundant clinical
trials that are inevitably linked to ethical questions. These aspects deserve further consideration in
future work on the interplay of distinct intellectual property rights and the private as well as the
social costs of developing new drugs.
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A Appendix: Figures
Figure A-1: Distribution of clinical trials lengths
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Notes: This figure shows the distribution of lengths of clinical trials by phase at aggregated indications level. Observations are at
the aggregated indications level. Lengths calculated as the medians of the full sample of clinical trials in Cortellis. Only aggregated
indications that are part of the opposition sample included.
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Figure A-2: Distribution of patent-drug relationships by opposition outcome
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Notes: This figure shows the distribution of patent-drug relationships by opposition outcome. Patent-drug relationship as stated in
Cortellis. Observations are at the drug-patent level. Bold relationships indicate “primary patent status”. The null-hypothesis that the
two distributions are equal can be rejected with a p-value of 0.143 (Chi2 = 14.712).
Figure A-3: Annual number of opposed patents and rate of examiner participation
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Notes: This graph includes all opposition proceedings (at the patent-level) in the regression sample. Based on the same sample, the
figure also shows the annual rate of examiner participation in opposition proceedings.
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Figure A-4: Project advancement at the drug-indication level by sample
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Notes: Observations are at the drug-indication level. “All drugs” refers to all non-pending drug projects with development information in
the Cortellis database. “All drugs with patent link” refers to all non-pending drug projects where a link to a patent family was identified.
“All drugs with patent opposition” refers to all non-pending drug projects with at least one patent challenged in opposition proceedings.
“All drugs in final sample” refers to all non-pending drug projects that are part of our final sample of analysis. Higher approval rates for
drug projects with opposed patents compared to our final sample are due to the fact that companies adapt their innovation efforts only
conditional on opposition outcome.
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B Appendix: Tables
Table B-1: Groups of control variables
Group name Variables in group
Patent characteristics Dummy for PCT application
Dummy for accelerated examination
Dummy for examination in Munich
Dummies for publication language
Size of docdb family
Number of IPC classes
Number of claims
Number of inventors
log(1 + Number of patent literature references)
log(1 + Number of patent literature 3yrs forward citations)
Patent examination characteristics Duration of examination
Duration of wait until examination
Patent age effects Dummies for age in years
Year effects Dummies for patent grant year
Dummies for opposition outcome year
Drug characteristics Number of indications
Dummy for prior approval
Number of patents
Dummy for orphan drug status
Dummy for paediatric use status
Development characteristics Time since discovery
Dummies for current development stage
Disease effects Dummies for aggregated ICD-9 levels (19)
Technology effects Dummies for technology class (34)
Dummy for biologics
Originator characteristics Dummies for originator country
Dummy for originator corporation
Dummies for originator portfolio size:
small – large
Opponent characteristics Number of opponents
Dummies for opponent country
Dummy for opponent corporation
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Table B-2: Impact of patent invalidation on drug development by timing as well as portfolio size
(1) (2) (3) (4) (5) (6) (7) (8)
Dep var Approval Next Stage
Sample Small Large Small Large
Pre-clinic/Phase I Phase II/III Pre-clinic/Phase I Phase II/III Pre-clinic/Phase I Phase II/III Pre-clinic/Phase I Phase II/III
Dep var mean 0.311 0.287 0.599 0.336 0.311 0.287 0.599 0.336
Invalidated −0.301∗ 0.329 0.023 0.047 −0.302 0.612 0.393 −0.261
(0.179) (0.530) (0.342) (0.206) (0.198) (0.693) (0.357) (0.231)
Invalidated × Potential LoE (in yrs) 0.006 −0.073 −0.065∗∗ −0.035 −0.021 −0.082 −0.081∗∗∗ −0.015
(0.037) (0.055) (0.030) (0.028) (0.042) (0.064) (0.030) (0.031)
Potential LoE (in yrs) 0.041 0.037 0.099∗∗∗ 0.022 0.011 0.030 0.059∗∗ −0.015
(0.026) (0.049) (0.024) (0.024) (0.031) (0.055) (0.024) (0.026)
Drug characteristics Yes∗∗ Yes∗∗∗ Yes∗∗∗ Yes Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes
Development characteristics Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗
Patent characteristics Yes∗∗∗ Yes∗∗∗ Yes Yes∗∗∗ Yes∗∗ Yes∗∗∗ Yes∗∗ Yes∗∗
Technology effects Yes Yes∗ Yes∗∗∗ Yes Yes∗ Yes∗∗∗ Yes∗∗∗ Yes
Disease effects Yes∗∗∗ Yes∗∗∗ Yes Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗ Yes∗∗∗
Examination characteristics Yes Yes Yes Yes Yes Yes∗ Yes∗∗ Yes
Age effects Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes Yes∗ Yes∗∗∗ Yes Yes∗∗∗
Originator characteristics Yes∗∗ Yes∗∗∗ Yes Yes Yes∗∗∗ Yes∗∗ Yes Yes
Opponent characteristics Yes∗∗∗ Yes Yes Yes Yes∗∗ Yes Yes∗∗ Yes∗
Year effects Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗
Underidentification test 15.7 6.8 10.8 16.5 15.7 6.8 10.8 16.5
Weak identification test 11.5 3.9 6.2 9.2 11.5 3.9 6.2 9.2
Observations 1,668 677 2,302 1,312 1,668 677 2,302 1,312
Observations (weighted) 672 404 890 753 672 404 890 753
Notes: Columns (1) to (8) show 2SLS regressions for the impact of invalidation on drug development on subsamples defined by the development stage of the drug project at the time of opposition
outcome and the size of the originator. The samples used in columns (1), (3), (5) and (7) include drug projects only if the patent opposition outcome occurred during the pre-clinical phase or in clinical
phase I. Likewise, the samples used in columns (2), (4), (6) and (8) include drug projects only if the patent opposition outcome occurred during clinical phase II or III. The samples used in columns (1),
(2), (5) and (6) include drug projects only if the drug originates from small entities. Likewise, the samples used in columns (3), (4), (7) and (8) include drug projects only if the drug originates from
large entities. In each 2SLS regression the Invalidated dummy is instrumented with the corresponding probability predicted by a probit regression on the Examiner participation dummy and all other
exogenous variables. The underidentification and weak identification tests are the heteroskedasticity-robust Kleibergen and Paap (2006) rk LM and Wald F statistics, respectively, as reported by Stata’s
ivreg2 command (Baum et al., 2010). A comprehensive list of the control variables contained in the indicated groups can be found in Table B-1 in the Appendix. Standard errors are two-way clustered
by drug and indication. Observations are weighted by the inverse frequency at drug-indication-patent-level. Significance levels: * p<0.1, ** p<0.05, *** p<0.01.
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Table B-3: Impact of patent invalidation on drug development – first indication only
(1) (2) (3) (4) (5) (6) (7) (8)
Estimation method OLS IV OLS IV OLS IV OLS IV
Dep var Approval Next Stage
Dep var mean 0.422 0.422 0.422 0.422 0.559 0.559 0.559 0.559
Invalidated −0.053 −0.230 −0.020 −0.012 −0.009 −0.103 0.028 0.143
(0.041) (0.148) (0.050) (0.190) (0.042) (0.151) (0.052) (0.198)
Invalidated × Potential LoE (in yrs) −0.007 −0.047∗ −0.014 −0.063∗∗
(0.011) (0.026) (0.011) (0.026)
Potential LoE (in yrs) 0.029∗∗ 0.058∗∗∗ −0.003 0.035
(0.012) (0.022) (0.011) (0.022)
Drug characteristics Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗
Development characteristics Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗
Patent characteristics Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗ Yes∗∗∗ Yes∗∗ Yes∗∗∗
Technology effects Yes Yes∗∗∗ Yes Yes∗∗∗ Yes Yes∗∗∗ Yes Yes∗∗∗
Disease effects Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗
Examination characteristics Yes Yes Yes Yes Yes∗ Yes∗ Yes∗ Yes
Age effects Yes Yes Yes Yes∗∗ Yes Yes∗ Yes Yes∗∗
Originator characteristics Yes∗∗ Yes∗ Yes∗∗ Yes∗ Yes∗∗ Yes∗∗ Yes∗∗ Yes∗
Opponent characteristics Yes Yes Yes Yes Yes Yes Yes Yes
Year effects Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗
Underidentification test 37.4 28.6 37.4 28.6
Weak identification test 43.0 16.5 43.0 16.5
Observations 1,566 1,566 1,566 1,566 1,566 1,566 1,566 1,566
Observations (weighted) 901 901 901 901 901 901 901 901
Notes: Columns (1) and (2) as well as (5) and (6) provide a comparison between the OLS and the 2SLS regressions for the impact of invalidation on drug development (approval or continuation to
next stage) when accounting for the actual loss of exclusivity. Columns (3) and (4) as well (7) and (8) include an interaction term capturing the loss of exclusivity in linear form. First indication refers
to the drug-indication project that was first initiated for a particular compound. In each 2SLS regression the Invalidated dummy is instrumented with the corresponding probability predicted by a probit
regression on the Examiner participation dummy and all other exogenous variables. The underidentification and weak identification tests are the heteroskedasticity-robust Kleibergen and Paap (2006) rk
LM and Wald F statistics, respectively, as reported by Stata’s ivreg2 command (Baum et al., 2010). A comprehensive list of the control variables contained in the indicated groups can be found in Table
B-1 in the Appendix. Standard errors are two-way clustered by drug and indication. Observations are weighted by the inverse frequency at drug-indication-patent-level. Significance levels: * p<0.1, **
p<0.05, *** p<0.01.
4
5
Table B-4: Impact of patent invalidation on drug development – primary patent only
(1) (2) (3) (4) (5) (6) (7) (8)
Estimation method OLS IV OLS IV OLS IV OLS IV
Dep var Approval Next Stage
Dep var mean 0.305 0.305 0.305 0.305 0.503 0.503 0.503 0.503
Invalidated −0.055 −0.143 −0.021 −0.067 −0.007 0.097 0.016 0.197
(0.034) (0.140) (0.036) (0.156) (0.036) (0.165) (0.042) (0.191)
Invalidated × Potential LoE (in yrs) −0.013 −0.036∗ −0.010 −0.045∗∗
(0.010) (0.019) (0.010) (0.019)
Potential LoE (in yrs) 0.037∗∗∗ 0.055∗∗∗ −0.003 0.024
(0.010) (0.017) (0.010) (0.017)
Drug characteristics Yes∗∗∗ Yes∗∗∗ Yes∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗
Development characteristics Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗
Patent characteristics Yes∗∗ Yes∗∗ Yes∗∗ Yes∗∗∗ Yes∗∗ Yes∗∗ Yes∗∗ Yes∗∗
Technology effects Yes Yes∗ Yes Yes∗∗ Yes Yes Yes Yes
Disease effects Yes∗∗∗ Yes∗∗∗ Yes∗∗ Yes∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗
Examination characteristics Yes Yes Yes Yes Yes Yes Yes Yes
Age effects Yes∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes Yes Yes Yes
Originator characteristics Yes∗∗ Yes∗∗ Yes∗∗ Yes∗∗ Yes∗∗ Yes∗∗∗ Yes∗∗ Yes∗∗∗
Opponent characteristics Yes∗ Yes∗ Yes Yes Yes Yes Yes Yes
Year effects Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗
Underidentification test 22.5 19.0 22.5 19.0
Weak identification test 28.7 12.1 28.7 12.1
Observations 2,522 2,522 2,522 2,522 2,522 2,522 2,522 2,522
Observations (weighted) 2,522 2,522 2,522 2,522 2,522 2,522 2,522 2,522
Notes: Columns (1) and (2) as well as (5) and (6) provide a comparison between the OLS and the 2SLS regressions for the impact of invalidation on drug development (approval or continuation to
next stage) when accounting for the actual loss of exclusivity. Columns (3) and (4) as well (7) and (8) include an interaction term capturing the loss of exclusivity in linear form. Primary patent refers to
patents that protect the formulation or product of the underlying drug. In each 2SLS regression the Invalidated dummy is instrumented with the corresponding probability predicted by a probit regression
on the Examiner participation dummy and all other exogenous variables. The underidentification and weak identification tests are the heteroskedasticity-robust Kleibergen and Paap (2006) rk LM and
Wald F statistics, respectively, as reported by Stata’s ivreg2 command (Baum et al., 2010). A comprehensive list of the control variables contained in the indicated groups can be found in Table B-1 in the
Appendix. Standard errors are two-way clustered by drug and indication. Observations are weighted by the inverse frequency at drug-indication-patent-level. Significance levels: * p<0.1, ** p<0.05,
*** p<0.01.
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Table B-5: Impact of patent invalidation on drug development – approval in Europe
(1) (2) (3) (4) (5) (6) (7) (8)
Estimation method OLS IV OLS IV OLS IV OLS IV
Dep var Approval Next Stage
Dep var mean 0.129 0.129 0.129 0.129 0.459 0.459 0.459 0.459
Invalidated 0.005 −0.019 0.033 0.049 0.011 −0.068 0.047 0.058
(0.021) (0.096) (0.021) (0.099) (0.030) (0.123) (0.036) (0.135)
Invalidated × Potential LoE (in yrs) −0.011 −0.026∗ −0.015∗ −0.044∗∗∗
(0.007) (0.015) (0.008) (0.014)
Potential LoE (in yrs) 0.021∗∗∗ 0.032∗∗∗ 0.007 0.029∗∗∗
(0.007) (0.013) (0.008) (0.011)
Drug characteristics Yes∗∗ Yes∗∗ Yes∗∗ Yes∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗
Development characteristics Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗
Patent characteristics Yes Yes Yes Yes Yes∗ Yes∗∗ Yes∗∗ Yes∗∗
Technology effects Yes Yes Yes Yes∗∗∗ Yes Yes Yes Yes
Disease effects Yes∗ Yes∗ Yes Yes∗ Yes∗∗ Yes∗∗∗ Yes∗∗ Yes∗∗∗
Examination characteristics Yes Yes Yes Yes Yes Yes Yes Yes
Age effects Yes Yes Yes Yes Yes Yes Yes Yes
Originator characteristics Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗
Opponent characteristics Yes∗ Yes∗ Yes∗ Yes∗ Yes Yes Yes Yes
Year effects Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗
Underidentification test 36.5 33.9 36.5 33.9
Weak identification test 52.8 24.6 52.8 24.6
Observations 5,959 5,959 5,959 5,959 5,959 5,959 5,959 5,959
Observations (weighted) 2,719 2,719 2,719 2,719 2,719 2,719 2,719 2,719
Notes: Columns (1) and (2) as well as (5) and (6) provide a comparison between the OLS and the 2SLS regressions for the impact of invalidation on drug development (approval or continuation to
next stage) when accounting for the actual loss of exclusivity. Columns (3) and (4) as well (7) and (8) include an interaction term capturing the loss of exclusivity in linear form. Drug projects that have
not reached approval in Europe have the dependent variable set to 0. In each 2SLS regression the Invalidated dummy is instrumented with the corresponding probability predicted by a probit regression
on the Examiner participation dummy and all other exogenous variables. The underidentification and weak identification tests are the heteroskedasticity-robust Kleibergen and Paap (2006) rk LM and
Wald F statistics, respectively, as reported by Stata’s ivreg2 command (Baum et al., 2010). A comprehensive list of the control variables contained in the indicated groups can be found in Table B-1 in the
Appendix. Standard errors are two-way clustered by drug and indication. Observations are weighted by the inverse frequency at drug-indication-patent-level. Significance levels: * p<0.1, ** p<0.05,
*** p<0.01.
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Table B-6: Impact of patent invalidation on drug development – biological drugs only
(1) (2) (3) (4) (5) (6) (7) (8)
Estimation method OLS IV OLS IV OLS IV OLS IV
Dep var Approval Next Stage
Dep var mean 0.261 0.261 0.261 0.261 0.477 0.477 0.477 0.477
Invalidated 0.050 0.013 0.089∗∗ 0.061 0.090∗ 0.027 0.123∗∗ 0.142
(0.039) (0.109) (0.045) (0.119) (0.049) (0.132) (0.057) (0.148)
Invalidated × Potential LoE (in yrs) −0.023 −0.052∗ −0.022 −0.072∗∗
(0.017) (0.027) (0.017) (0.030)
Potential LoE (in yrs) 0.036∗∗ 0.060∗∗ −0.003 0.040
(0.018) (0.026) (0.015) (0.027)
Drug characteristics Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗
Development characteristics Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗
Patent characteristics Yes Yes Yes Yes∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗
Technology effects Yes Yes Yes Yes Yes Yes Yes Yes
Disease effects Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗
Examination characteristics Yes∗ Yes Yes∗ Yes Yes Yes Yes Yes
Age effects Yes Yes Yes Yes Yes Yes Yes Yes
Originator characteristics Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗
Opponent characteristics Yes Yes Yes Yes Yes Yes Yes Yes
Year effects Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗
Underidentification test 31.6 31.7 31.6 31.7
Weak identification test 49.6 27.4 49.6 27.4
Observations 2,326 2,326 2,326 2,326 2,326 2,326 2,326 2,326
Observations (weighted) 1,138 1,138 1,138 1,138 1,138 1,138 1,138 1,138
Notes: Columns (1) and (2) as well as (5) and (6) provide a comparison between the OLS and the 2SLS regressions for the impact of invalidation on drug development (approval or continuation to next
stage) when accounting for the actual loss of exclusivity. Columns (3) and (4) as well (7) and (8) include an interaction term capturing the loss of exclusivity in linear form. The sample includes only
drug projects on large molecule drugs (“biologics”). In each 2SLS regression the Invalidated dummy is instrumented with the corresponding probability predicted by a probit regression on the Examiner
participation dummy and all other exogenous variables. The underidentification and weak identification tests are the heteroskedasticity-robust Kleibergen and Paap (2006) rk LM and Wald F statistics,
respectively, as reported by Stata’s ivreg2 command (Baum et al., 2010). A comprehensive list of the control variables contained in the indicated groups can be found in Table B-1 in the Appendix.
Standard errors are two-way clustered by drug and indication. Observations are weighted by the inverse frequency at drug-indication-patent-level. Significance levels: * p<0.1, ** p<0.05, *** p<0.01.
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Table B-7: Impact of patent invalidation on drug development – relative loss of exclusivity
(1) (2) (3) (4) (5) (6) (7) (8)
Estimation method OLS IV OLS IV OLS IV OLS IV
Dep var Approval Next Stage
Dep var mean 0.305 0.305 0.305 0.305 0.507 0.507 0.507 0.507
Invalidated −0.018 −0.151 0.022 −0.035 0.011 −0.129 0.043 0.029
(0.030) (0.121) (0.032) (0.125) (0.034) (0.125) (0.040) (0.141)
Invalidated × Potential LoE (relative) −0.226∗ −0.658∗∗∗ −0.186 −0.726∗∗∗
(0.126) (0.244) (0.131) (0.230)
Potential LoE (in yrs) 0.586∗∗∗ 0.930∗∗∗ −0.011 0.419∗∗
(0.121) (0.203) (0.124) (0.194)
Drug characteristics Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗
Development characteristics Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗
Patent characteristics Yes∗∗ Yes∗∗ Yes∗∗ Yes∗∗ Yes∗∗ Yes∗∗ Yes∗∗ Yes∗∗∗
Technology effects Yes Yes∗ Yes Yes∗∗∗ Yes Yes Yes Yes
Disease effects Yes∗∗∗ Yes∗∗∗ Yes∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗
Examination characteristics Yes Yes Yes Yes Yes Yes Yes Yes
Age effects Yes Yes∗∗ Yes Yes∗∗∗ Yes Yes Yes Yes
Originator characteristics Yes∗∗ Yes∗ Yes∗∗ Yes∗∗ Yes∗∗ Yes∗∗ Yes∗∗ Yes∗∗
Opponent characteristics Yes Yes Yes Yes Yes Yes Yes Yes
Year effects Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗ Yes∗∗∗
Underidentification test 36.5 34.1 36.5 34.1
Weak identification test 52.8 24.8 52.8 24.8
Observations 5,959 5,959 5,959 5,959 5,959 5,959 5,959 5,959
Observations (weighted) 2,719 2,719 2,719 2,719 2,719 2,719 2,719 2,719
Notes: Columns (1-8) provide a comparison between the OLS and the 2SLS regressions for the impact of invalidation on drug development (approval or continuation to next stage) when accounting for
the actual loss of exclusivity as a share of the total market exclusivity. Columns (3) and (4) as well (7) and (8) include an interaction term capturing the relative loss of exclusivity in linear form. In each
2SLS regression the Invalidated dummy is instrumented with the corresponding probability predicted by a probit regression on the Examiner participation dummy and all other exogenous variables. The
underidentification and weak identification tests are the heteroskedasticity-robust Kleibergen and Paap (2006) rk LM and Wald F statistics, respectively, as reported by Stata’s ivreg2 command (Baum
et al., 2010). A comprehensive list of the control variables contained in the indicated groups can be found in Table B-1 in the Appendix. Standard errors are two-way clustered by drug and indication.
Observations are weighted by the inverse frequency at drug-indication-patent-level. Significance levels: * p<0.1, ** p<0.05, *** p<0.01.
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C Appendix: Incentives to invest in innovation
We present the incentives to invest into R&D in a highly stylized model which has its roots in the
model by Nordhaus (1969). In this model, investments in R&D need to be made which stochasti-
cally yield successful innovations before the innovator can earn profits conditional on having been
successful in innovating. We rely on this highly simplified model to analyze how changes in the
duration of exclusivity an innovator enjoys before imitation can occur affect her incentives to invest
in R&D.
Investments in R&D: We denote the amount of risky R&D as I that has to be invested in t = 0
and the probability of successfully innovating in t = 0 as p. p is a concave function of a firm’s
investments I with p′(I)> 0 and p′′(I)< 0. (This implies that the firm’s cost function I(p) is strictly
convex with I ′(p)> 0 and I ′′(p)> 0).
We acknowledge that the assumption of investments and innovation outcomes happening instan-
taneously in t = 0 is an abstraction from the lengthy R&D process in the pharmaceutical industry
that we describe in Section 2 of this paper. Budish et al. (2015) provide a more nuanced model that
takes the commercialization lag (i.e., the time between discovery and drug approval) into account;
regarding the incentive effect of the duration of exclusivity, it leads to the same conclusions as the
simple model presented here.
Returns from R&D: In case of successful innovation, the profits of an innovator depend on
the level of exclusivity of the innovation. In case of full exclusivity (no imitation is possible for
competitors), the innovator earns monopoly profits assumed to equal pim. If (partial) imitation
is possible, the innovator earns some competitive return pic with 0 ≤ pic < pim. The duration of
exclusivity in case of successful innovation is T . As described in Section 2, T is derived from patent
protection as well as data exclusivity and depends on the project specific speed of commercialization.
Abstracting from the obsolescence of an innovation (a drug might be replaced by a more efficient
drug in which case profits would be reduced to zero; see Budish et al. (2015)) and assuming a
discount rate of r, a successful innovator therefore earns a total profit Π(T ) of
Π(T ) =
∫ T
0
e−r tpimd t +
∫
∞
T
e−r tpicd t.
Private incentives to invest in R&D: The firm’s problem is to choose p so as to maximize the
expected pay-off from investing into R&D pΠ(T )− I(p). The FOC to this problem is given by
I ′(p∗) = Π(T ).
The optimal likelihood of successful innovation p∗(T ) clearly increases in the duration of exclusivity
T during which monopoly profits pim can be earned. Since pic < pim, Π(T ) increases in T with
∂Π(T )
∂ T > 0. The longer the period of exclusivity, the higher the innovator’s return and, hence, its
incentive to invest into R&D. Since p(I) is concave, the FOC holds for increasing T only for rising I .
The opposite holds as well. A loss of exclusivity will reduce a firm’s incentives to invest in R&D.
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